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ABSTRACT

PREDICTION IN THERAPEUTIC EFFECTIVENESS RESEARCH: PROLONGED DOSE
TITRATION IN WARFARIN PATIENTS AND MODEL TRANSPORTABILITY
Brian Steven Finkelman
Stephen Kimmel

Therapeutic effectiveness research relies heavily on prediction modeling, as improving
therapeutic outcomes for individuals often requires being able to predict which patients are likely
to do poorly on a given therapy. In this dissertation, we examine the specific case of patients
starting warfarin therapy, many of whom are at higher risk of bleeding and thrombotic events
because they take a long time to determine their optimal therapeutic dose. Additionally, we
examine the general problem of transportability of clinical prediction models and whether that
problem can be improved through sequential model updating. Specifically, we conducted three
projects with the following goals: 1) To determine the social, clinical, and genetic factors
associated with time to maintenance dose in patients starting warfarin; 2) To develop and
externally validate a prediction model of prolonged dose-titration in these patients; and 3) To
determine whether sequential model updating can improve model transportability in a simulation
study. Being able to predict which patients are likely to experience prolonged dose titration on
warfarin could help clinicians and patients decide whether to use warfarin or a less burdensome
alternative oral anticoagulant. Furthermore, the overall utility of this and other clinical prediction
models could be greatly increased by strategies that improve model transportability, such as
sequential model updating.
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CHAPTER 1. INTRODUCTION

What is therapeutic effectiveness research? The goal of therapeutic effectiveness research is to
improve public health by increasing the effectiveness of existing therapies as used in clinical
practice. The effectiveness of a therapy is different from its efficacy, which refers to the average
effect of a therapy under ideal usage. Efficacy is generally assessed, along with safety, by
randomized controlled trials to determine whether therapies should be allowed to be brought to
market. Research on therapeutic effectiveness, thus, seeks to identify the factors that lead to the
observed discrepancy between a therapy’s efficacy and its effectiveness in real-world usage.
Therapeutic effectiveness will often depend on a much wider range of factors than efficacy,
including clinical factors, such as age, comorbidities, and drug-drug interactions; genetic factors,
such as variants in genes related to a drug’s pharmacodynamic or pharmacokinetic pathways; and
social/behavioral factors, such as access to health care, health literacy, and medication adherence
[Bosworth et al., 2011; Ma & Lu, 2011]. As a result, improving the overall effectiveness of a
therapy in a population will often necessitate identifying patient subpopulations for whom the
therapy is likely to have limited effectiveness, and then utilizing alternative treatment strategies—
such as dosing or management changes, interventions designed to improve adherence, or even
alternative therapies—in those patients.

The role of prediction modeling in therapeutic effectiveness research. Because improving
therapeutic effectiveness often requires identifying patient subpopulations in whom the therapy is
generally more or less effective than would be expected in an idealized clinical trial scenario,
prediction modeling is of vital importance to therapeutic effectiveness research. Clinical
prediction models are most often based on regression methods, in which the outcome of
interest—for instance, response to therapy or the development of side effects—is modeled as a
1

function of several predictor variables, in order to predict the probability of the outcome for a
given individual. To be useful clinically, these models must be developed in a rigorous fashion
and demonstrate generalizability, or the ability to perform well in the patient population of
interest, not just the study cohort used to develop the model. Models are typically assessed both in
terms of calibration, which refers to how well predicted probabilities match observed
probabilities, and discrimination, which refers to how successful the model is at correctly ranking
relatively lower and higher risk individuals. Additionally, model generalizability is typically
assessed via external validation, in which the model is tested in a cohort of patients that were not
used in the model development process. Finally, it is important to test whether use of the
prediction model actually leads to better outcomes in practice. While observational studies can
play an important role, testing of prediction model performance is most rigorously done through a
randomized controlled trial, comparing outcomes on patients who have been randomized to
receive therapy that has been tailored based on the results of prediction models to those who
receive standard therapy without prediction. Examples include clinical trials of whether
pharmacogenetic dosing algorithms for warfarin led to improvement in anticoagulation control
over clinical dosing algorithms or standard clinical practice [Kimmel et al., 2013; Pirmohamed et
al., 2013]. Special attention should be paid in such trials to the generalizability of the study
population, since effectiveness, not efficacy, is the metric of interest. Furthermore, the time and
monetary costs of conducting such trials can often be prohibitive, especially considering that
model performance can deteriorate over time, requiring recalibration.

Warfarin is a common oral anticoagulant that has served as a model for therapeutic effectiveness
research. Warfarin sodium is a commonly prescribed anticoagulant used for the primary and
secondary prevention of thromboembolic disease, and until recently, it was the only available oral
anticoagulant in the US [Mohapatra, Tran, Gore, & Spencer, 2005]. The drug has been used in
2

practice for 60 years; however, it remains difficult to use because of an unusually narrow
therapeutic range and as much as a 30-fold variability in dosing requirements for patients to
achieve stable therapeutic levels of anticoagulation [Wadelius et al., 2004]. Over-anticoagulation
from having too high a dose of warfarin can result in life-threatening bleeding complications,
such as intracranial hemorrhage, while under-anticoagulation from having too low a dose of
warfarin reduces the efficacy of the therapy, leaving patients at risk for strokes and other
thromboembolic events [Higashi et al., 2002; Sconce et al., 2005; White et al., 1987]. Even nonserious adverse events such as minor bleeding can lead to warfarin discontinuation [Gullov,
Koefoed, & Petersen, 1999]. As a result of these limitations, much research has been devoted to
improving the effectiveness of warfarin therapy in practice. Most of this research has focused on
the development of models to predict a patient’s required warfarin dose, with the idea that
knowing the required therapeutic dose in advance will make it easier to titrate a given patient to a
therapeutic level when starting therapy [Gage et al., 2008; Klein et al., 2009]. Pharmacogenetic
dosing models for warfarin are typically able to predict within 20% of patients’ actual therapeutic
dose in about half of individuals [Finkelman, Gage, Johnson, Brensinger, & Kimmel, 2011],
although their accuracy has historically been much lower in African Americans [Klein et al.,
2009; Limdi et al., 2008; Schelleman, Chen, et al., 2008; Suarez-Kurtz & Botton, 2013].

Current dosing strategies for warfarin often result in a lengthy and dangerous dose titration
period. Despite the availability of dosing algorithms, warfarin is still typically dosed empirically,
with patients started at the population average dose of 5mg/day and then titrated either up or
down based on changes in the international normalized ratio (INR) [Fihn et al., 1993]. As a result,
patients often experience a lengthy dose titration period of weeks to months at the onset of
warfarin therapy, during which time they are at particularly high risk of complications from
improper anticoagulation levels. For instance, it has been estimated that bleeding risk is
3

approximately 2-6 times higher during the first 3 months of warfarin therapy, and the rate of
thromboembolic events has been shown to be elevated very early in a patient’s course of warfarin
therapy in some contexts, such as following surgery [Brotman, Jaffer, Hurbanek, & Morra, 2004;
Fihn et al., 1993]. In addition, a prolonged dose titration phase substantially increases patient
burden by increasing the frequency of required visits for INR monitoring for an extended period
of time. As a result, such patients may have increased medical costs, reduced quality of life
[Dantas, Thompson, Manson, Tracy, & Upshur, 2004], greater dissatisfaction, and higher rates of
warfarin discontinuation [Arnsten, Gelfand, & Singer, 1997; Fang et al., 2010], thus depriving
these patients of the benefit of a highly efficacious therapy.

Patients at high risk of having a lengthy dose titration period on warfarin therapy may be more
appropriately treated with alternative oral anticoagulation agents. In 2010, the FDA approved
dabigatran, a direct thrombin inhibitor, for patients with non-valvular atrial fibrillation. Thus,
dabigatran became the first oral anticoagulant to be approved in the U.S. since the introduction of
warfarin. Rivaroxaban, a Factor Xa inhibitor, was approved by the FDA in November 2011, and
another Factor Xa inhibitor, apixaban, was recently approved by the FDA in December 2012.
Both dabigatran and rivaroxaban have been shown to be non-inferior to warfarin for prevention of
thromboembolic events [Connolly et al., 2009; Patel et al., 2011], while apixaban was shown to
be superior to warfarin for stroke prevention in the setting of a randomized trial [Granger et al.,
2011]. Bleeding rates were also generally low and either comparable to or lower than warfarin
[Siegal & Crowther, 2013]. Moreover, these alternative agents all have the advantage of having
much less variability in their dosing requirement for patients [Cove & Hylek, 2013]—although
recent evidence suggests that at least dabigatran may have more dosing variability than had been
previously thought [Charlton & Redberg, 2014; Cohen, 2014a, 2014b; Moore, Cohen, &
Mattison, 2014]—allowing for fixed dosing regimens and eliminating the monitoring burden of
4

anticoagulation. Furthermore, these newer agents also have fewer food and drug interactions,
meaning that they might necessitate fewer lifestyle adjustments and be less prone to fluctuations
in anticoagulation levels over the long term.

However, the newer agents have some issues that have prevented them from completely replacing
warfarin in clinical practice. All of the drugs are substantially more expensive, as annual direct
pill costs for the newer agents are about 60 times more expensive than warfarin [Avorn, 2011].
Furthermore, more of the cost of the newer agents are shifted to patients, since co-pays on the
expensive new medications are generally much higher than co-pays for the laboratory testing
required with warfarin [Avorn, 2011]. Additionally, dabigatran has shown problems of frequent
gastrointestinal side effects and appears to have an increased risk of myocardial infarction relative
to warfarin [Ansell, 2010; Uchino & Hernandez, 2012], while rivaroxaban may have an increased
risk of spinal hematoma [Jaeger, Jeanneret, & Schaeren, 2011; Steffel & Braunwald, 2011].
Furthermore, it is too soon to know what the full risk profile for apixaban might be in real-world
clinical practice.

Ironically, many clinicians have been made uncomfortable by the inability to monitor
anticoagulation level in individual patients on the alternative agents. With warfarin, monitoring
allowed physicians the opportunity to tailor therapy to those, for example, with increased
bleeding risk or renal dysfunction; to identify and potentially address problems with therapy
before they led to bleeding or thrombotic events; and to determine whether events that did occur
were due to non-therapeutic drug levels [Ansell, 2010]. Removing the frequent contact with
health care providers that comes with monitoring might also worsen adherence to the newer
anticoagulants [Cutler et al., 2014], and poor adherence could theoretically increase the risk of
adverse outcomes for patients on the newer anticoagulants relative to those on warfarin, due to
5

the shorter half-lives of the newer drugs [Ansell, 2010]. The lack of an antidote to the alternative
agents has also led to concern about an inability to stop anticoagulation for patients who develop
serious bleeding [Steffel & Braunwald, 2011], including those who are victims of trauma [Cotton,
McCarthy, & Holcomb, 2011]; thus, development of antidotes is an active area of current
research [Lu et al., 2013]. As a result of all of these issues, there is uncertainty in the clinical
community about when to use these newer anticoagulants instead of warfarin [Ansell, 2010;
Hankey & Eikelboom, 2010; Kanagasabapathy, Chowdary, & Gatt, 2011; Mangiafico &
Mangiafico, 2012].

Our research is motivated by the hypothesis that individual patients who are likely to respond
poorly to warfarin could potentially be better treated with less burdensome but more expensive
alternative oral anticoagulants, though we will not formally address this specific hypothesis in
this dissertation. Recent research has suggested that the cost-effectiveness of dabigatran relative
to warfarin is greatest when used in patients who would have had poor INR control on warfarin
[Freeman et al., 2011; Shah & Gage, 2011], and there is no reason to expect that this would be
different for rivaroxaban and apixaban. Thus, predicting warfarin response in individual patients
prior to initiating anticoagulation therapy may be an optimal and cost-effective approach to
incorporating alternative oral anticoagulants alongside warfarin in clinical practice.

Existing research is inadequate for identifying patients at high risk of prolonged dose titration on
warfarin therapy. While there has been extensive research to determine the factors that affect
required therapeutic maintenance dose [Gage et al., 2008, 2004; Kimmel et al., 2008; Klein et al.,
2009; Lenzini et al., 2010; Rieder et al., 2005; Schelleman et al., 2010; Schelleman, Chen, et al.,
2008; Schelleman, Limdi, & Kimmel, 2008; Voora et al., 2005], much less is known about the
factors that lead to a prolonged dose titration phase for patients starting warfarin. Some evidence
6

suggests that genetic variants associated with maintenance dose may also be associated with
prolongation of the dose titration period. For instance, the APOE ε3 allele has been associated
with delay of reaching maintenance dose in African Americans [Cavallari et al., 2011]. Mutations
in CYP2C9 have also been associated with increased time to maintenance dose [Higashi et al.,
2002; Meckley, Wittkowsky, Rieder, Rettie, & Veenstra, 2008], and variants in VKORC1 have
been associated with increased time to first therapeutic INR [Schwarz et al., 2008], although the
results for these variants have been mixed [Limdi et al., 2008]. Variants in these genes have also
been associated with more frequent dosing changes and greater time spent out of therapeutic INR
range [Limdi, Wiener, Goldstein, Acton, & Beasley, 2009; Schwarz et al., 2008]. However,
factors that are associated with outcomes in population studies often perform poorly when
predicting future outcomes in individuals [Pepe, Janes, Longton, Leisenring, & Newcomb, 2004].
Thus, it is essential to directly test whether these genetic variants could be clinically useful for
predicting a prolonged dose titration period in individual patients at the onset of therapy.

Furthermore, given the multifactorial nature of warfarin response, it seems implausible that
genetic variants are the only important predictors of a prolonged dose titration phase. However,
potentially important clinical and sociodemographic factors have not, to our knowledge, been
studied in this context. There is indirect evidence, though, including results from our group, that
poor adherence to warfarin could lead to prolongation of the dose titration period, as it has been
associated with significantly worse anticoagulation control [Cavallari et al., 2009; Kimmel et al.,
2007]. Additionally, we and others have shown that baseline clinical and sociodemographic
factors—such as younger age, greater than high school education, current employment, and
cognitive impairment—are associated with subsequent poor warfarin adherence [Arnsten et al.,
1997; Platt et al., 2008], as has been seen with other medications [Ediger et al., 2007; Kulkarni,
Alexander, Lytle, Heiss, & Peterson, 2006; Nikolaus et al., 1996]. However, these prediction
7

models have not shown very good discrimination in individual warfarin patients [Platt et al.,
2010]. Finally, a variety of social and clinical factors have been associated with several other
endpoints that may be related to a prolonged dose titration phase, including time in therapeutic
INR range, risk of bleeding events, and discontinuation of warfarin therapy [Beyth, Quinn, &
Landefeld, 1998; Fang et al., 2010; Gage et al., 2006; Lip, Frison, Halperin, & Lane, 2011;
Shireman et al., 2006].

In this dissertation, we aim to improve our ability to predict prolonged dose titration on warfarin
therapy as well as better understand its causes. When beginning this research, we hypothesized
that baseline clinical, genetic, and social factors could predict prolonged dose titration, which we
define as failure to reach stable therapeutic maintenance dose within 3 months of initiating
warfarin therapy. In Chapter 2, we focus on identifying both baseline and post-initiation factors
that are associated with time to the achievement of maintenance dose. Better knowledge of which
factors lead to a longer time to maintenance dose could help clinicians identify patients who are at
high risk of prolonged dose titration. Moreover, knowledge of reversible factors that are
associated with prolonged dose titration, such as behavioral factors, could potentially even
provide targets for interventions designed to improve anticoagulation control in patients on
warfarin. In Chapter 3, we focus on developing and externally validating a prediction model for
prolonged dose titration when starting warfarin therapy. Accurate prediction of prolonged dose
titration could help clinicians decide when to use alternative strategies for anticoagulation, such
as less burdensome but more expensive alternative oral anticoagulants, genetic testing to try to
improve dosing on warfarin, or more frequent INR monitoring.

Prediction models for individual response to warfarin therapy will need to be able to generalize
across a wide variety of clinical settings to maximize their clinical utility. There are over 30
8

million prescriptions for warfarin in the U.S. every year, with common indications including
stroke prophylaxis in atrial fibrillation, the presence of a mechanical heart valve, and treatment
for thromboembolic disease [Wysowski, Nourjah, & Swartz, 2007]. Patients on warfarin are
managed by specialty anticoagulation clinics, primary care physicians, cardiologists,
hematologists, and pharmacists, among others. As a result, it is likely that prediction models
developed in one clinical setting may not perform well in other settings, which could diminish
their overall usefulness in clinical practice. Deterioration of prediction model performance across
different clinical settings is an example of poor model transportability, which is a component of
model generalizability that refers to a model’s ability to produce accurate and reliable predictions
in different populations from the one in which the model was derived [Justice, Covinsky, &
Berlin, 1999]. Ultimately, the transportability of a prediction model can only be assessed using
validation data from distinct populations.

Utility of clinical prediction models is hampered by concerns about poor transportability across
broad areas of clinical medicine. The problem of poor transportability of prediction models is
much broader than just predicting warfarin response. For instance, the American Heart
Association (AHA) and the American College of Cardiology’s (ACC) most recent cholesterol
management guidelines were largely dependent on an individual’s predicted 10-year risk of
cardiovascular events [Stone et al., 2014]. However, the prediction models used in these
guidelines have been criticized because of concerns that they over-predict the risk of
cardiovascular disease in cohorts other than those used to develop the prediction model [Ridker &
Cook, 2013]. Additionally, there are several documented examples of validated prediction models
failing to generalize to different populations. For example, the EuroSCORE model, which was
developed in European populations to predict 30-day mortality in patients undergoing cardiac
surgery, failed to generalize to Australian surgical patients [Yap et al., 2006]. In another example,
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a clinical prediction rule for predicting deep vein thrombosis (DVT) performed well in the
secondary referral patient population in which it was developed, but failed to generalize to a
primary care setting [Oudega, Hoes, & Moons, 2005]. Furthermore, this problem is likely even
more widespread because of the many clinical outcomes that are known to vary substantially
across clinical sites, including readmission after hospitalization for heart failure [Ross et al.,
2008], mortality following surgery for colorectal cancer [Schootman et al., 2014], false-positive
results from mammographic screening [Roman, Skaane, & Hofvind, 2014], graft failure after
liver transplantation [Asrani et al., 2013], and medication adherence rates among diabetes patients
[Sherman, Sekili, Prakash, & Rausch, 2011]. As a result, methods to improve prediction model
transportability could be expected to impact a wide range of areas in clinical medicine, and could
be especially transformative for therapeutic effectiveness research.

Methods to improve prediction model transportability. Poor transportability of a prediction model
often occurs because of a problem of underfitting rather than overfitting [Justice et al., 1999]. In
other words, important predictors are either unknown, misspecified, or excluded from the original
model, and model performance degrades when tested in new populations with a different
conditional prevalence of those predictors. As a result, it can be very difficult to find statistical
solutions to problems of transportability using the derivation sample, because by definition, the
model needs to be tested on a sample with a different empirical distribution from the derivation
sample in order to determine its transportability. Thus, established methods such as Bayesian
model averaging [Hoeting, Madigan, Raftery, & Volinsky, 1999], bootstrap aggregation or
bagging [Breiman, 1996], and cross-validation [Borra & Di Ciaccio, 2010], which are effective at
reducing model overfitting, would not necessarily be expected to lead to improvements in model
transportability.
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In Chapter 4, we examine sequential model updating of mixed-effects models as a potential
strategy for improving prediction model transportability. In this approach, predictions are made
on individuals using the best available model at that time. Then, when their outcome data
becomes available, the model is re-estimated incorporating the newly available data. In short,
sequential model updating solves the problem of derivation datasets not being representative of
the population of interest by incorporating data from the population of interest into the derivation
dataset over time. In practice, sequential model updating would likely involve integrating the
prediction model into an electronic health records system (EHR) that spans multiple clinical sites.
Predictions for specific patients could be made using data already available in the EHR, and
outcomes would be automatically captured as they occur. This scheme would have the advantage
of automatically calibrating to local conditions, thus improving the transportability of the model,
without the need to recruit additional cohorts for constructing and validating separate prediction
models at each individual site. Our research attempts to quantify these potential gains in
prediction accuracy, as well as the types of scenarios where they might be expected to work best.
The results of this research could potentially enable future prediction models to be more reliable
in real-world clinical practice, both for oral anticoagulation research and for therapeutic
effectiveness research in general.
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CHAPTER 2. FACTORS AFFECTING TIME TO MAINTENANCE DOSE
IN PATIENTS INITIATING WARFARIN

Brian S Finkelman, Benjamin French, Luanne Bershaw, and Stephen E Kimmel

ABSTRACT
Background. Patients starting warfarin often experience lengthy dose-titration periods, when they
are at high risk for bleeding and thromboembolism. However, relatively little is known about why
some patients take longer than others to reach maintenance dose. Thus, we sought to identify
social, clinical, and genetic factors associated with prolonged time to maintenance dose (TTM).

Methods. We conducted a time-to-event analysis, using a prospective cohort of patients initiating
warfarin (N = 390). Additionally, we examined whether changes in post-initiation factors were
associated with TTM. Finally, we performed a secondary analysis in a subcohort (N = 156)
assessing the effect of adherence on TTM.

Results. No genetic or post-initiation factors were significantly associated with TTM. However,
previous use of warfarin (HR = 0.64; 95% CI 0.46, 0.88), current smoking status (HR = 0.61;
95% CI 0.39, 0.96), fewer than 4 doctor’s visits in the previous year (HR = 0.63 vs 4-12 visits;
95% CI 0.46, 0.88), and worse general health status (HR = 0.63; 95% CI 0.47, 0.84) were
significantly associated with longer TTM. Use of illegal injectable drugs (HR = 2.51; 95% CI
1.17, 5.39) was associated with shorter TTM. On secondary analysis, the hazard ratio for better
adherence and TTM was 1.70 (95% CI 0.88, 3.27).
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Conclusions. Pre-existing behavioral factors, health care utilization, and health quality were
associated with TTM in patients initiating warfarin, but clinical comorbidities and genetic factors
were not. Future studies are needed to determine whether warfarin patients with prolonged TTM
would have better outcomes on alternative agents.

BACKGROUND
Patients initiating warfarin often experience lengthy dose-titration periods of weeks to months,
during which time they are at particularly high risk of both bleeding and thromboembolic
complications from improper anticoagulation levels [Fihn et al., 1993; Hylek, Skates, Sheehan, &
Singer, 1996]. Additionally, during the dose-titration phase, patients may have their international
normalized ratio (INR) monitored as frequently as 1-2 times per week, while INR monitoring
during the maintenance phase of therapy is generally only once every 1-2 months. As a result of
this substantial increase in monitoring burden, patients with a long time to maintenance dose
(TTM) may have increased medical costs, reduced quality of life [Dantas et al., 2004], greater
dissatisfaction, and higher rates of warfarin discontinuation [Arnsten et al., 1997; Fang et al.,
2010]. Furthermore, given the recent availability of alternative oral anticoagulants—including
dabigatran, rivaroxiban, and apixaban—a better understanding of the causes of prolonged TTM in
warfarin therapy is of increasing importance, because it could potentially help identify patient
subsets who might be better treated with alternative agents that, while more costly, do not require
monitoring of drug or anticoagulation levels.

In contrast to the large amount of research that has been done on the genetic and clinical factors
relating to warfarin maintenance dose requirement [Lee & Klein, 2013], relatively little is
understood about the factors that lead to a longer TTM. Previous research on the association
between genetic variants and TTM has been mixed [Cavallari et al., 2011; Higashi et al., 2002;
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Jorgensen et al., 2009; Limdi et al., 2008; Meckley et al., 2008], with few studies conducted in
prospective cohorts. Given the multifactorial nature of warfarin response, however, it seems
implausible that genetic variants are the only important factors associated with TTM. Indeed, a
variety of non-genetic factors, including social and clinical factors, have been associated with
several other endpoints that may be related to prolonged TTM, including poor warfarin adherence
[Cavallari et al., 2009; Kimmel et al., 2007], time in therapeutic INR range [Apostolakis,
Sullivan, Olshansky, & Lip, 2013; Witt et al., 2009], and risk of bleeding events [Beyth et al.,
1998; Gage et al., 2006; Lip et al., 2011; Shireman et al., 2006]. However, such factors have not,
to our knowledge, been rigorously studied in the specific context of TTM.

We sought to examine the association between social, clinical, and genetic factors and TTM for
patients initiating warfarin. Additionally, we aimed to identify whether changes in factors after
warfarin initiation could lead to increased TTM. Identifying such factors could help identify
patient subsets that might be better treated with warfarin versus one of the newer anticoagulants.
To accomplish these aims, we conducted a time-to-event analysis of the INR Adherence and
Genetics (IN-RANGE) cohort, a large prospective cohort of adults initiating warfarin [Kimmel et
al., 2007; Platt et al., 2008].

METHODS
IN-RANGE cohort. The IN-RANGE cohort of warfarin patients has been used to study the
clinical and genetic predictors of warfarin maintenance dose and adherence [Kealey et al., 2007;
Kimmel et al., 2007, 2008; Parker et al., 2007; Platt et al., 2008, 2010; Schelleman et al., 2010,
2007; Schelleman, Chen, et al., 2008]. Participants were recruited from specialty anticoagulation
clinics at the Hospital of the University of Pennsylvania (HUP), the Philadelphia Veterans Affairs
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Medical Center (PVAMC), and Hershey Medical Center. Institutional review board approval was
obtained at all three sites, and all study participants provided written informed consent. Exclusion
criteria included being under 21 years old, being unwilling or unable to provide consent, having
an abnormal INR prior to starting warfarin or heparin therapy, or the presence of antiphospholipid
antibodies. Participants were enrolled between April 2002 and February 2006. All participants in
the original IN-RANGE cohort (N = 390) were eligible for inclusion in the current study.

Primary outcome. The primary outcome was the time from warfarin initiation to the first
maintenance dose-defining visit, in days. Patients were considered to have achieved maintenance
dose if they had three consecutive INRs within the target therapeutic range, with no constraint on
the amount of time between INRs. This definition was prespecified prior to cohort enrollment.
Having a longer TTM is generally worse for patients because of increases in bleeding and
thrombosis risk as well as patient burden. TTM was a secondary outcome of the original INRANGE study; however, a priori power calculations demonstrated adequate power to detect
clinically meaningful hazard ratios (Table 2.1).

Exposures. A total of 38 pre-existing, or ‘baseline,’ variables were considered for analysis. These
included social, clinical, and genetic factors, which were all assessed at the time of recruitment
(Tables 2.2 and 2.3). Genetic factors studied were the VKORC1 -1639G>A variant (rs9923231),
the CYP2C9*2 and CYP2C9*3 variants (rs1799853 and rs1057910, respectively), and the APOE
ε2 and ε4 alleles (based on the rs7412 and rs429358 variants, respectively). As described
previously [Kimmel et al., 2008], DNA was extracted from buccal swab preparations and
analyzed using PCR amplification by collaborators who were blinded to patient characteristics
and outcomes. All non-genetic factors were ascertained via self-report, making the data
comparable to what would be available to clinicians managing warfarin patients.
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Table 2.1. Power calculation for primary analysis
Percent Exposed

Minimum Detectable
Maximum Detectable
Hazard Ratio > 1
Hazard Ratio < 1
50%
1.4
0.71
35%
1.4
0.71
25%
1.5
0.67
15%
1.6
0.63
10%
1.7
0.59
Calculations are based on a type I error rate of 0.05, 300 subjects
reaching maintenance dose, and 80% power. Calculations were
performed using PASS 11.
Table 2.2. Baseline social and genetic factors considered as candidate variables for primary analysis and
their specifications.
Factor
Social
Self-reported race
Gender
Marital status
Employment status
Education status
Annual income per household
member
Insurance status
Ever used illegal injectable drugs
Number of alcoholic drinks per
week
Current smoking status
Self-reported general health status
No. hospitalizations in past 12
months
No. doctor’s visits in past 12
months
Had difficulty receiving health
care in the past 12 months
Genetic
VKORC1 -1639G>A variant
CYP2C9*2 and CYP2C9*3
variants
APOE ε2 allele
APOE ε4 allele

Specification
Binary (0 = not African American; 1 = African American)
Binary (0 = male; 1 = female)
Categorical (1 = married (ref); 2 = separated/divorced;
3 = widowed; 4 = never married)
Categorical (1 = working; 2 = unemployed; 3 = retired (ref);
4 = disabled)
Binary (0 = more than high school; 1 = high school or less)
Categorical (1 = < $15,000; 2 = $15,000 to $20,000;
3 = > $20,000 (ref))
Categorical (1 = private (ref); 2 = any VA; 3 = Medicaid; 4 =
Medicare only; 5 = no insurance)
Binary (0 = no; 1 = yes)
Binary (0 = 0–7 drinks; 1 = more than 7 drinks)
Binary (0 = not current smoker; 1 = current smoker)
Binary (0 = excellent/very good/good; 1 = fair/poor)
Continuous (linear)
Categorical (1 = 0–3 visits; 2 = 4–12 visits (ref);
3 = 13 or more visits)
Binary (0 = no; 1 = yes)

Binary (0 = no variants; 1 = at least one variant)
Binary (0 = no variants; 1 = at least one variant)
Binary (0 = no copies; 1 = at least one copy)
Binary (0 = no copies; 1 = at least one copy)
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Table 2.3. Baseline clinical factors considered as candidate variables for primary analysis and their
specifications.
Factor
Clinical
Age (years) at baseline visit
Body Mass Index
Previous use of warfarin
Warfarin indication

Number of interacting
medications being used at baseline
Amiodarone use at baseline
Statin use at baseline
CHADS2 score
History of pulmonary embolism
History of deep vein thrombosis
History of peptic ulcer disease
History of gastritis
History of stroke
History of cancer
History of hypertension
History of diabetes
History of arrhythmia
History of congestive heart failure
History of myocardial infarction
History of any other heart disease

Specification
Continuous (linear)
Continuous (linear)
Binary (0 = no; 1 = yes)
Categorical (1 = atrial fibrillation/atrial flutter (ref);
2 = post deep vein thrombosis/pulmonary embolism;
3 = dilated cardiomyopathy/left ventricular thrombosis;
4 = stroke/transient ischemic attack; 5 = other)
Binary (0 = 0–1 medications; 1 = 2 or more medications)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Categorical (1 = 0 (ref); 2 = 1; 3 = 2 or higher)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)
Binary (0 = no; 1 = yes)

Additionally, several ‘post-initiation’ factors were studied, including changes in the use of
interacting medications, quantitative and qualitative changes in diet, changes in weight, and
changes in alcohol consumption since starting warfarin. Changes in interacting medications were
defined as starting or stopping an interacting medication after warfarin initiation; the list of
potentially interacting medications is shown in the Appendix. Finally, warfarin adherence,
measured by medication event monitoring system (MEMS) caps [Kimmel et al., 2007], was
considered in a secondary analysis because adherence data were only available in 40% of the
cohort (N = 156). Some patients did not have MEMS cap data because the devices first became
available after enrollment had begun, while others were offered to use the device but declined.
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Primary Analysis. Cox regression models, stratified by clinical site, were used for all analyses.
Variable selection for the primary model of baseline factors was performed using a combination
forward-backward algorithm. Specifically, univariable analyses were performed on baseline
candidate variables, and those with P < 0.2 via the likelihood ratio test were included in the full
model. The variable in the full model with the largest P-value via the likelihood ratio test was
successively removed until all P-values were less than 0.1. Next, all previously omitted variables
were reintroduced one at a time. Those variables with P < 0.1 in this forward step were included
in the final model, as were age and race, which were deemed clinically important. The variables
included in the final model were age, race, previous use of warfarin, current smoking status,
illegal injectable drug use, number of doctor’s visits in the previous year, general health status,
history of arrhythmia, and having a variant in VKORC1. Complete-case analysis was used
because only 32 individuals (9% of cohort) were missing data on any of these variables.

To ensure that we could compare the effect of genetic factors with what has previously been
observed in the literature, genetic factors were analyzed separately, adjusted for final model
variables. Genetic factors were specified as binary variables, indicating whether at least one
variant was present, in order to avoid data sparseness when assessing prespecified interactions
between genotype and race. For the same reason, CYP2C9*2 and *3 variants were combined into
a single binary variable. The effects of post-initiation factors, adjusted for final model variables,
were also analyzed separately. All post-initiation factors were specified as time-dependent
variables, with their value representing the total number of changes that an individual had
experienced by a given date. Additionally, because of their time-dependent specification, models
for post-initiation factors were adjusted for visit number to help prevent confounding by varying
frequency of INR monitoring [Fihn et al., 1993].

18

Finally, because this study used the same cohort for variable selection and model estimation,
there was concern about model overfitting and sensitivity to outliers. Thus, all reported point
estimates, confidence intervals, and P-values in the primary analysis were estimated using 1,000
bootstrap replications [Efron & Tibshirani, 1994]. Specifically, to perform the bootstrap
procedure, individuals were repeatedly sampled with replacement, meaning that the same
individuals could be selected multiple times in a given sample. The Cox model was then fit using
this bootstrap sample, and hazard ratio estimates were recorded. This procedure was then
repeated 1,000 times. Reported hazard ratio point estimates were calculated as the mean hazard
ratio estimate from 1,000 bootstrap samples; confidence intervals and P-values were calculated
based on the mean and variance of 1,000 bootstrap samples, assuming a normal distribution of the
bootstrap samples. This method was chosen to improve the stability and interpretability of
stratified estimates based on model interactions; however, use of quantiles from the empirical
distribution for producing confidence intervals would have left the results for the main effects
essentially unchanged (data not shown). These mean estimates are also slightly more stable than
those using model-based estimates in the original sample. Additionally, confidence intervals and
P-values are slightly more conservative than what would otherwise be observed.

Secondary Analyses. Warfarin adherence was analyzed using the subcohort of patients with
available MEMS cap data (N = 156), adjusting for final model variables. Adherence was
specified as a time-dependent binary variable, indicating whether an individual had been ≥80%
adherent over the past three visits. Age was excluded from adjusted adherence models to reduce
the potential bias from adjustment of near-instruments [Myers et al., 2011; Pearl, 2011], because
it is known to be a strong predictor of warfarin adherence [Platt et al., 2008, 2010], while not
being associated with the outcome. Use of illegal injectable drugs was also excluded because of
unstable estimates due to data sparseness in the subcohort. Finally, we performed a secondary
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analysis examining whether individuals with high (≥49 mg/wk) or low (≤21 mg/wk) maintenance
dose had increased TTM. As in the primary analysis, point estimates, confidence intervals, and Pvalues for all secondary analyses were based on 1,000 bootstrap replications.

Sensitivity Analyses. We conducted a sensitivity analysis using inverse probability of censoring
weights to determine the potential impact of informative censoring on our results [Cain & Cole,
2009; Robins & Finkelstein, 2000]. In this analysis, a Cox model was constructed with time until
censoring, rather than TTM, as the outcome of interest. All candidate baseline variables, postinitiation variables, adherence, visit number, INR, and warfarin dose were considered for
inclusion in the model. Factor variables with >1% missingness were given missing indicators, as
well, because missing data were felt to be potentially predictive of censoring. Variables were
selected using an analogous combination forward-backward algorithm, with less restrictive
criteria of P < 0.25 for entry and retention. This model was then used to predict individual
probabilities of censoring at each patient-visit, which could then be used to construct inverse
probability weights, using the formula:
( )
{

( ( )
( ( )

)
| ( ))

( )

for which wt indicates the weight for a patient at time t, C(t) indicates whether an individual was
censored at time t, and X(t) indicates an individual’s covariates, time-varying or otherwise, at
time t. These weights were then applied to the final model in the primary analysis to see how
much incorporation of the weights changed the original hazard ratio estimates.

A sensitivity analysis was also performed treating visit number, rather than days, as the unit of
time for the primary analysis, in order to look at the impact of potentially variable visit
frequencies on our results. Additionally, we performed a sensitivity analysis where standard, non20

bootstrapped model-based estimates were calculated. Finally, the individual effects of CYP2C9*2
and CYP2C9*3, as well as using an additive specification (i.e. 0, 1, or 2) for all genetic variants,
were assessed in a sensitivity analysis. All analyses were performed using R 3.0.2 [R
Development Core Team, 2014].

RESULTS
There were 390 subjects in the cohort, whose characteristics are shown in Table 2.4. Median
TTM was 45 days (IQR 15, 135), with 288 subjects (74%) achieving maintenance dose by the
end of the study. Median number of visits required to achieve maintenance dose was 7 (IQR 4,
13). Genotype frequencies by race are shown in Table 2.5.

The results for the final model are shown in Table 2.6. Complete data on all variables in the final
model were available in 358 subjects (91%), with 267 (75%) achieving maintenance dose by the
end of the study. Note that because this is a time-to-event analysis where the “event” is reaching
maintenance dose, hazard ratios below 1 indicate that a factor is associated with longer TTM and
is worse for patients, on average. This is in contrast to most studies where the event of interest is
harmful (i.e. mortality), and hazard ratios below 1 would be considered protective. Previous use
of warfarin (HR = 0.64 vs no previous use of warfarin; 95% CI 0.46, 0.88), current smoking
status (HR = 0.61 vs current non-smoking status; 95% CI 0.39, 0.96), having fewer than 4
doctor’s visits in the previous year (HR = 0.63 vs 4-12 visits; 95% CI 0.46, 0.88), and having
fair/poor general health status (HR = 0.63 vs excellent/very good/good general health; 95% CI
0.47, 0.84) were significantly associated with longer TTM. In contrast, use of illegal injectable
drugs (HR = 2.51 vs no reported drug use; 95% CI 1.17, 5.39) was associated with shorter TTM.
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Table 2.4. Characteristics of the IN-RANGE clinical cohort (N = 390).
Characteristic

N (%) or
Mean (SD)
59.2 (15.0)
119 (31)

Characteristic

N (%) or
Mean (SD)

Age (years)
CYP2C9 genotype:
Female gender
*1*1
283 (76)
Race:
*1*2
59 (16)
African American
174 (45)
*1*3
26 (7)
Caucasian
206 (53)
*2*3
3 (1)
Other
10 (3)
VKORC1 -1639G>A genotype:
Body Mass Index:
GG
209 (56)
< 25
122 (32)
GA
149 (40)
25–30
125 (32)
AA
15 (4)
> 30
140 (36)
Insurance status:
Warfarin indication:
Private
215 (56)
Atrial fibrillation/flutter
188 (48)
Any VA
107 (28)
DVT/PE
116 (30)
Medicaid
16 (4)
DCM/LV thrombosis
26 (7)
Medicare only
17 (4)
Stroke/TIA
22 (6)
None
29 (8)
Other
38 (10)
Employment status:
Target INR 2–3
389 (99.7)
Working
128 (33)
Maintenance dose (mg/wk)
39.9 (22.0)
Unemployed
34 (9)
Previous use of warfarin
96 (25)
Retired
143 (37)
History of hypertension
192 (49)
Disabled
81 (21)
History of diabetes
107 (27)
Income per household member:
History of PUD
36 (9)
< $15,000/year
109 (33)
History of CHF
78 (20)
$15,000–$20,000/year
99 (30)
> 1 Interacting medications
210 (54)
> $20,000/year
122 (37)
Smoking status:
AC clinic site:
Never smoked
141 (36)
HUP
184 (47)
Past smoker
185 (47)
PVAMC
137 (35)
Current smoker
64 (16)
Hershey
69 (18)
Abbreviations:anticoagulation (AC), congestive heart failure (CHF), deep vein thrombosis
(DVT), dilated cardiomyopathy (DCM), Hospital of the University of Pennsylvania (HUP), left
ventricular (LV), peptic ulcer disease (PUD), Philadelphia Veterans Administration Medical
Center (PVAMC), pulmonary embolism (PE), and transient ischemic attack (TIA).

22

Table 2.5. Frequencies of VKORC1, CYP2C9, and APOE genotypes stratified by race.
Genotype

Not African American
N (%)a

African American
N (%)a

VKORC1 -1639G>A
GG
73 (36)
136 (80)
GA
116 (57)
33 (20)
AA
15 (7.4)
0 (0.0)
CYP2C9
*1*1
128 (63)
155 (92)
*1*2
47 (23)
12 (7.1)
*1*3
25 (12)
1 (0.6)
*2*3
3 (1.5)
0 (0.0)
APOE
ε2/ε2
1 (0.5)
4 (2.4)
ε2/ε3
25 (12)
22 (13)
ε2/ε4
3 (1.5)
11 (6.5)
ε3/ε3
131 (64)
80 (47)
ε3/ε4
45 (22)
46 (27)
ε4/ε4
1 (0.5)
7 (4.1)
a
Percents are rounded to the nearest percent for values ≥10% and to the
nearest tenth of a percent for values below that cut-off. As a result,
percents may not appear to add up to exactly 100%.

23

Table 2.6. Unadjusted and adjusted hazard ratios for time to maintenance dose for variables included in the
final model.
Baseline Factora
N (%) or
Unadjustedc
Adjustedc
b
d
e
(N = 358)
Mean (SD)
Hazard Ratio
P-value
Hazard Ratiod
P-valuee
Age (years)
59 (15)
1.01 (1.00, 1.01)
0.24
1.01 (1.00, 1.02)
0.15
Race
African American
159 (44)
0.85 (0.65, 1.11)
0.24
1.02 (0.73, 1.42)
0.90
Caucasian or other
199 (56)
—
—
Previous use of warfarin
Yes
89 (25)
0.69 (0.52, 0.93)
0.015
0.64 (0.46, 0.88)
0.007
No
269 (75)
—
—
Current smoking status
Yes
61 (17)
0.72 (0.47, 1.09)
0.12
0.61 (0.39, 0.96)
0.031
No
297 (83)
—
—
Self-reported illegal
injectable drug use
Yes
17 (5)
1.65 (0.73, 3.73)
0.23
2.51 (1.17, 5.39)
0.018
No
341 (95)
—
—
No. doctor’s visits in
previous year:
<4
95 (27)
0.71 (0.52, 0.96)
0.085
0.63 (0.46, 0.88)
0.024
4 – 12
174 (49)
—
—
> 12
89 (25)
0.86 (0.62, 1.20)
0.88 (0.61, 1.28)
General health
Fair/poor
114 (32)
0.66 (0.50, 0.88)
0.005
0.63 (0.47, 0.84)
0.002
Excellent/very good/
244 (68)
—
—
good
History of arrhythmia
Yes
189 (53)
0.90 (0.70, 1.16)
0.43
0.79 (0.59, 1.05)
0.10
No
169 (47)
—
—
No. variants in VKORC1
≥1
159 (44)
1.23 (0.95, 1.59)
0.11
1.33 (0.99, 1.78)
0.061
0
199 (56)
—
—
a
All non-genetic factors are based on self-report.
b
Both unadjusted and adjusted results are from the same complete-case dataset to improve
comparability.
c
All models are stratified by anticoagulation clinic site.
d
Hazard ratios and confidence intervals are based on the mean and variance from 1,000 bootstrap
replications. Hazard ratios less than 1 indicate longer time to maintenance dose; hazard ratios greater
than 1 indicate shorter time to maintenance dose.
e
All P-values are based on the Wald test using the mean and variance of estimates from 1,000 bootstrap
replications. Categorical variables were tested jointly.

There was evidence to suggest that the proportional hazards assumption may be violated for our
primary analysis (P = 0.01), but inspection of survival curves for individual covariates indicated
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that this should not have a qualitative effect on our results. The effects of genetic factors alone,
stratified by race, are shown in Table 2.7. No genetic variant was significantly associated with
TTM either before or after adjustment for covariates (All Pmain effect > 0.06), and no significant
interactions between genetic variants and race were observed (All Pinteraction > 0.4). As shown in
Table 2.8, no post-initiation factor was statistically significant either before or after adjustment
for covariates (All P > 0.2).

In secondary analyses, better adherence appeared significantly associated with shorter TTM in an
unadjusted analysis (HR = 1.95; 95% CI 1.06, 3.59), but it was no longer significant after
adjustment for covariates (HR = 1.70; 95% CI 0.88, 3.27), as shown in Table 2.9. By contrast,
final maintenance dose was not significantly associated with TTM in either unadjusted [high dose
HR = 1.03 (95% CI 0.79, 1.34); low dose HR = 1.13 (95% CI 0.78, 1.64); overall P = 0.81] or
adjusted [high dose HR = 1.10 (95% CI 0.78, 1.54); low dose HR = 1.11 (95% CI 0.73, 1.69);
overall P = 0.79] analyses.

In sensitivity analyses, use of inverse probability of censoring weights did not appreciably change
the results from those shown in Table 2.6, with a 3.3% mean change in hazard ratio estimates, as
shown in Table 2.10. Additionally, use of visit number, rather than days, as the unit of time did
not substantially change the results, with a 6.8% mean change in hazard ratio estimates (data not
shown). Our results were also not substantially changed when standard, non-bootstrapped
estimates were used, with a 1.1% mean change in hazard ratio estimates (data not shown).
Finally, use of an additive specification for genetic variants and having separate variables for the
CYP2C9*2 and CYP2C9*3 variants did not substantially change the results, with small
quantitative changes toward the null (data not shown).
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Table 2.7. Unadjusted and adjusted hazard ratios for time to maintenance dose for genetic factors, stratified
by race.
African
Unadjusted
Adjustedd
b
c
American
Hazard Ratio
Pinteraction
Hazard Ratiob
Pinteractionc
No
1.09 (0.81, 1.46)
0.42
1.31 (0.93, 1.85)
0.85
Yes
1.41 (0.78, 2.54)
1.40 (0.71, 2.77)
Any CYP2C9
No
0.97 (0.69, 1.36)
0.99
1.05 (0.73, 1.52)
0.49
Yes
0.96 (0.53, 1.73)
0.68 (0.35, 1.35)
Any APOE ε2
No
1.08 (0.68, 1.73)
0.93
0.91 (0.52, 1.58)
0.46
Yes
1.11 (0.62, 2.01)
1.21 (0.61, 2.40)
Any APOE ε4
No
1.01 (0.71, 1.44)
0.93
0.97 (0.67, 1.42)
0.92
Yes
1.03 (0.57, 1.86)
1.00 (0.51, 1.98)
a
Both unadjusted and adjusted results are from the same complete-case dataset to improve
comparability.
b
Hazard ratios and confidence intervals are based on the mean and variance from 1,000 bootstrap
replications. Hazard ratios less than 1 indicate longer time to maintenance dose; hazard ratios
greater than 1 indicate shorter time to maintenance dose.
c
P-values for interactions are based on the Wald test using the mean and variance of interaction
terms from 1,000 bootstrap replications.
d
Adjusted for all baseline factors shown in Table 2.6.
Genetic Variant
(N = 358)a
Any VKORC1

Table 2.8. Unadjusted and adjusted hazard ratios for time to maintenance dose for post-initiation factors.
Post-Initiation
Unadjusted
Adjustede
Median time
Factor
to first changeb
Hazard Ratioc
P-valued
Hazard Ratioc
P-valued
(N = 358)a
Change in interact47 (28, 83)
0.93 (0.70, 1.24)
0.62
1.01 (0.76, 1.34)
0.95
ing medication
Change in diet:
Qualitative
14 (7, 34)
0.97 (0.80, 1.17)
0.73
1.00 (0.82, 1.23)
>0.99
Quantitative
14 (7, 36)
0.91 (0.78, 1.07)
0.24
0.98 (0.84, 1.15)
0.82
Change in weight
17 (7, 35)
0.93 (0.82, 1.06)
0.26
0.97 (0.83, 1.13)
0.70
Change in alcohol
50 (29, 86)
0.86 (0.60, 1.23)
0.42
0.96 (0.68, 1.34)
0.80
use
a
Both unadjusted and adjusted results are from the same complete-case dataset to improve
comparability.
b
Median time (IQR) in days from the initiation of warfarin to the first change experienced by an
individual for the given variable.
c
Hazard ratios are based on the mean estimate from 1,000 bootstrap replications. Hazard ratios less
than 1 indicate longer time to maintenance dose; hazard ratios greater than 1 indicate shorter time to
maintenance dose.
d
All P-values are based on the Wald test using the mean and variance of estimates from 1,000
bootstrap replications. Categorical variables were tested jointly.
e
Adjusted for all baseline factors shown in Table 2.6, plus visit number to prevent visit frequency from
confounding the time-varying covariates.
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Table 2.9. Unadjusted and adjusted hazard ratios for time to maintenance dose in subcohort with adherence
data.

Factora
(N = 143)b
≥ 80% adherencef
African American
Previous use of
warfarin
Current smoker

Unadjusted
Hazard
P-valued
Ratioc
1.95
0.032
(1.06, 3.59)
0.88
0.60
(0.54, 1.43)
0.67
0.12
(0.41, 1.11)
0.75
0.39
(0.39, 1.44)

Adjusted (– Adherence)
Hazard
P-valued
Ratioc
—
—
0.84
(0.44, 1.61)
0.58
(0.32, 1.03)
0.68
(0.31, 1.47)

No. doctor’s visits
in previous year:
<4

0.61
0.063
0.32

Adjusted (+ Adherence)e
Hazard
P-valued
Ratioc
1.70
0.11
(0.88, 3.27)
0.90
0.77
(0.46, 1.76)
0.59
0.084
(0.32, 1.07)
0.70
0.37
(0.33, 1.52)

0.52
0.026
0.47
0.026
0.51
0.053
(0.32, 0.85)
(0.27, 0.82)
(0.28, 0.91)
4 – 12
—
—
—
> 12
0.67
0.68
0.61
(0.35, 1.29)
(0.29, 1.57)
(0.27, 1.41)
Fair/poor general
0.64
0.055
0.63
0.10
0.69
0.20
health
(0.40, 1.01)
(0.36, 1.10)
(0.39, 1.22)
History of
1.14
0.55
1.01
0.97
1.00
>0.99
arrhythmia
(0.74, 1.78)
(0.57, 1.79)
(0.57, 1.76)
VKORC1 variant
0.96
0.84
1.06
0.85
1.01
0.97
(0.62, 1.47)
(0.57, 1.98)
(0.54, 1.88)
a
All non-genetic factors, excluding adherence, are based on self-report. Age was excluded from this
analysis to prevent over-adjustment, because it is a known strong predictor of warfarin adherence while
being very weakly associated with TTM. Illegal injectable drug use was excluded because there were
too few self-reported users in the subcohort to produce stable estimates.
b
Both unadjusted and adjusted results are from the same complete-case dataset to improve
comparability; only individuals with adherence data were included in this analysis.
c
Hazard ratios and confidence intervals are based on the mean and variance from 1,000 bootstrap
replications. Hazard ratios less than 1 indicate longer time to maintenance dose; hazard ratios greater
than 1 indicate shorter time to maintenance dose.
d
All P-values are based on the Wald test using the mean and variance of estimates from 1,000 bootstrap
replications. Categorical variables were tested jointly.
e
The adjusted model also included visit number to ensure that visit frequency was not confounding the
time-varying covariate.
f
Adherence was specified in a time-varying fashion, indicating whether the participant had correct
adherence on ≥ 80% of the days over the last 3 visits, using medication event monitoring system
(MEMS) data.
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Table 2.10. Adjusted hazard ratios for time to maintenance dose using inverse probability of censoring
weights.
Baseline Factora
Adjusted
(N = 358)
IPCW Hazard Ratiob
P-valuec
Age (years)
1.01 (1.00, 1.02)
0.16
African American
1.00 (0.72, 1.37)
0.98
Previous use of warfarin
0.66 (0.49, 0.91)
0.011
Current smoker
0.65 (0.44, 0.98)
0.040
Illegal injectable drug use
2.25 (1.20, 4.24)
0.012
No. doctor’s visits in
previous year:
<4
0.68 (0.51, 0.92)
0.038
4–12
—
> 12
0.94 (0.67, 1.34)
Fair/poor general health
0.62 (0.46, 0.82)
0.001
VKORC1 variant
1.32 (1.00, 1.74)
0.054
a
All non-genetic factors are based on self-report.
b
Hazard ratios less than 1 indicate longer time to maintenance dose;
hazard ratios greater than 1 indicate shorter time to maintenance dose.
Inverse probability of censoring weights were constructed from a Cox
model with covariates including income, difficulty obtaining health
care, previous warfarin use, warfarin indication, number of
hospitalizations in previous year, number of doctor’s visits in previous
year, statin use, history of pulmonary embolism, history of congestive
heart failure, VKORC1, APOE ε2, INR value, visit number, warfarin
adherence, and clinic site.
c
All P-values are based on the Wald test, using robust standard errors to
account for the non-independence of the weighted samples. Categorical
variables were tested jointly.

DISCUSSION
In this study, we examined the social, clinical, and genetic factors associated with TTM, using the
IN-RANGE prospective cohort of adults initiating warfarin therapy. We found that previous use
of warfarin, current smoking status, having fewer than 4 doctor’s visits in the previous year, and
worse general health status were all associated with longer TTM, while use of illegal injectable
drugs was associated with shorter TTM. To our knowledge, this study is the first systematic
examination of all of these factors for the clinically-relevant outcome of TTM in patients
initiating warfarin.
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Primary Analysis. Most of the literature on factors associated with TTM has focused on the
effects of genetic variants, and our findings for genetic variants are largely consistent with these
previous studies. None of the genetic variants studied were significantly associated with TTM.
Like other prospective studies [Jorgensen et al., 2009; Limdi et al., 2008], we failed to observe an
association between CYP2C9*2 or *3 and TTM in either African Americans or Caucasians.
While evidence suggests that CYP2C9*5, *6, *8, and *11 may be more important than
CYP2C9*2 and *3 for determining warfarin maintenance dose in African Americans due to their
higher prevalence [Cavallari et al., 2010], significant associations between these variants and
TTM have not been observed in previous studies [Limdi et al., 2008].

Similarly, VKORC1 was not significantly associated with TTM in either African Americans or
Caucasians, which is consistent with the overall literature [Cavallari et al., 2011; Higashi et al.,
2002; Jorgensen et al., 2009; Limdi et al., 2008; Meckley et al., 2008]. Our hazard ratio in
African Americans, however, was similar to that observed by Limdi et al. [Limdi et al., 2008],
although none of these results were statistically significant. Our study was sufficiently powered to
detect clinically meaningful hazard ratios, and even when adjusting for multiple variables we had
more than 26 events per degree of freedom in our model, well more than the generally
recommended 10 events per degree of freedom [Concato, Peduzzi, Holford, & Feinstein, 1995;
Peduzzi, Concato, Feinstein, & Holford, 1995]. Thus, if there is indeed a real effect, it seems
likely to be of small magnitude. Finally, our results did not confirm a previous finding of an
association between APOE and TTM in African Americans [Cavallari et al., 2011]. However, this
previous study excluded individuals who did not reach maintenance dose and had limited
adjustment for confounders. Therefore, the previous finding could have been the result of
selection bias, since many individuals who failed to reach maintenance dose could have had a
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prolonged dose titration period, or bias from unmeasured confounding of clinical, social, and
behavioral factors.

By contrast, non-genetic factors—including behavioral factors (e.g. smoking status), health care
utilization (e.g. number of doctor’s visits in the previous year), and health quality (e.g. selfreported general health status)—appeared to be more important than genetic factors for
determining TTM (Table 2.6). Worse general health status has been previously shown to be
associated with worse warfarin adherence [Platt et al., 2010], and current smoking status has been
associated with increased warfarin dose requirement [Gage et al., 2008; Nathisuwan et al., 2011]
as well as decreased time in therapeutic range [Apostolakis et al., 2013], so it is unsurprising that
these factors were found to be associated with longer TTM. Furthermore, fewer than 4 doctor’s
visits in the previous year might be a marker for reduced health care access or health literacy, so
it could conceivably be related to longer TTM through the effect of these factors on medication
adherence and INR monitoring burden. Having fewer doctor’s visits in the previous year may
also be associated with better general health status; however, the effects of being poorly
integrated into the health care system on TTM likely overwhelm any benefits of better health.

More surprising was the finding that previous use of warfarin was associated with longer, rather
than shorter, TTM. Previous warfarin users did not differ from new warfarin users in terms of
their warfarin indication or comorbidities (data not shown); however, they did appear to have
their INRs checked less frequently, with 32% of previous warfarin users being seen at least once
per week on average compared to 45% for new warfarin users, although this difference was not
statistically significant (Table 2.11). One can hypothesize that physicians may have monitored
patients with prior warfarin experience less frequently, thus leading to a longer TTM; however,
this explanation likely does not fully explain the observed association, as previous warfarin use
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Table 2.11. Association between significant factors and overall visit frequency.
Factora
(N = 390)

Median Number
of Visits to
Maintenance Doseb

Overall Visit Frequencyc
< 1 per week

≥ 1 per week

P-valued

Current smoker:
No
7 (4, 12)
180 (55)
146 (45)
0.21
Yes
8 (4, 21)
47 (73)
17 (27)
Illegal injectable
drug use:
No
7 (4, 13)
218 (59)
153 (41)
0.076
Yes
4 (3, 12)
8 (44)
10 (56)
Previous use of
warfarin:
No
7 (4, 11)
161 (55)
130 (45)
0.12
Yes
8 (4, 16)
65 (68)
31 (32)
No. doctor’s visits
in previous year:
<4
8 (5, 14)
62 (61)
39 (39)
0.70
4–12
6 (4, 10)
102 (55)
85 (45)
> 12
7 (3, 24)
61 (62)
37 (38)
General health:
Excellent/Very
6 (4, 11)
141 (55)
115 (45)
0.39
Good/Good
Fair/poor
9 (4, 16)
81 (64)
45 (36)
0.21
a
All factors from Table 2.6 that were found to be significantly associated with TTM were
included here.
b
Results are reported as median (IQR).
c
Results are reported as N (%) for each level of visit frequency for each covariate.
d
P-values are based on the likelihood ratio test from a logistic regression model, adjusted for
anticoagulation clinic site; categorical variables were tested jointly.

was still moderately associated with longer TTM in the sensitivity analysis using visit number,
rather than days, as the unit of time.

Similarly, the finding that patients who reported using illegal injectable drugs tended to have a
shorter TTM was counterintuitive. While it is possible that physicians were intentionally
monitoring these patients more closely, confirmatory evidence will be needed before concluding
that the observed association was not primarily due to chance. Changes in post-initiation factors
were also not associated with TTM, suggesting either that most of these changes typically do not
occur early enough in the course of therapy to have a substantial impact on TTM or that they are
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identified by physicians and appropriate dose adjustments are made during the dose titration
period. However, changes in post-initiation factors could still be important determinants of
anticoagulation control in patients on long-term warfarin therapy after maintenance dose has been
achieved and monitoring is typically less frequent. Finally, it is also worth noting that most
traditional clinical and demographic factors were not associated with TTM, including all clinical
comorbidities examined and use of interacting medications at baseline.

Secondary Analyses. Better adherence was not significantly associated with shorter TTM after
adjustment for covariates. However, given that the point estimate for adherence was comparable
to significant factors in the primary analysis, it seems plausible that there could be a real effect.
Because of their shorter half-lives and inability to monitor, there is some concern that
nonadherent patients on alternative oral anticoagulants might be expected to have worse
outcomes than nonadherent warfarin patients [Avorn, 2011]. Future studies are needed to clarify
the effect of adherence on TTM and the effects of adherence on outcomes with alternative oral
anticoagulants.

Limitations. There are several potential limitations of this study: 1) While one strength of our
study is that we included all available follow-up time in our analyses, there is still the possibility
of bias due to informative censoring. We attempted to assess the impact of informative censoring
by performing a sensitivity analysis incorporating inverse probability of censoring weights.
Because the results were not appreciably changed, we can be more confident that informative
censoring is not substantially biasing our results. 2) Because INRs were checked only at visits to
the anticoagulation clinic, there is the potential for interval censoring to bias our results. While
the potential bias was small due to visits typically being only about a week or two apart, we
attempted to determine the effect of interval censoring through a sensitivity analysis in which
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visit number was the unit of time for the analysis. The fact that the results were not substantially
changed makes us more confident in the robustness of our results. 3) We were limited to the
variables available in this cohort; thus, there may have been other important predictors of TTM
that we could not assess or residual confounding of the variables we did examine. For this reason,
future studies of TTM will likely need better measurement of social, behavioral, and health care
access factors, as well as medication adherence. 4) This study used the same dataset for variable
selection and effect estimation, potentially leading to problems with overfitting. To address this
issue, we bootstrapped all point estimates and confidence intervals in both primary and secondary
analyses. Bootstrapped results were not substantially different from standard estimates; however,
these results will still need independent validation. 5) Finally, these data are from specialty
anticoagulation clinics, potentially reducing their generalizability to warfarin patients in other
clinical settings.

Conclusions. In conclusion, TTM was associated with baseline behavioral factors, health care
utilization, and health quality in patients initiating warfarin, while traditional clinical
comorbidities and genetic factors appeared less important. The observed associations could
plausibly be related to differences in warfarin adherence and visit frequency that occur after
warfarin initiation, through their effects on anticoagulation control. Future studies will be needed
to address whether warfarin patients with prolonged TTM will have better outcomes on
alternative oral anticoagulants.
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CHAPTER 3. CAN WE PREDICT PROLONGED DOSE TITRATION IN
PATIENTS STARTING WARFARIN?

Brian S Finkelman, Benjamin French, Luanne Bershaw, Colleen M Brensinger,
and Stephen E Kimmel

ABSTRACT
Background. Patients initiating warfarin therapy generally experience a dose-titration period of
weeks to months, during which time they are at particularly high risk of both thromboembolic and
bleeding events. Accurate prediction of which patients are at higher risk of prolonged dose
titration could help clinicians determine which patients might be better treated by alternative
anticoagulation therapies that, while more costly, do not require dose titration.

Methods. Prolonged dose titration was defined as having a time to maintenance dose of greater
than 12 weeks. The prediction model was derived in a prospective cohort of patients initiating
warfarin (N = 390), using a Cox proportional hazards model to account for censoring, and then
validated in an external cohort (N = 663). Predictor variables were selected using a modified best
subsets algorithm, incorporating cross-validation to reduce overfitting.

Results. Five predictor variables were selected for inclusion in the prediction model: warfarin
indication, insurance status, number of doctor’s visits in the previous year, current smoking
status, and history of congestive heart failure. The AUC of this model in the derivation cohort, as
estimated using leave-one-out cross-validation, was 0.66 (95% CI 0.60, 0.74), while in the
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external validation cohort, the AUC was only 0.59 (95% CI 0.54, 0.64). Including genetic factors
in the model did not improve the AUC (0.59; 95% CI 0.54, 0.64). Examination of relative utility
indicated that use of the prediction model was unlikely to provide a clinically meaningful benefit
for patients.

Conclusion. Our results suggest that prolonged dose titration cannot be accurately predicted in
warfarin patients, at least using traditional clinical, social, and genetic predictors. Our results also
highlight the general need for external validation when constructing risk prediction models.

BACKGROUND
Because of the substantial population-level variability in warfarin dose requirement, patients
starting warfarin therapy will often experience a lengthy dose-titration period of weeks to months.
During this period, they are at particularly high risk of both bleeding and thromboembolic
complications from improper anticoagulation levels [Fihn et al., 1993; Hylek et al., 1996].
Patients with a prolonged dose-titration period also face increased burden from more frequent
international normalized ratio (INR) monitoring, which can lead to a reduced quality of life and
higher rates of discontinuation of a highly efficacious therapy [Arnsten et al., 1997; Dantas et al.,
2004; Fang et al., 2010]. Given the availability of less burdensome but more expensive alternative
oral anticoagulants [Avorn, 2011]—including dabigatran, rivaroxaban, and apixaban—accurate
prediction of which patients are likely to experience a prolonged dose-titration period on warfarin
could potentially help clinicians decide when to use warfarin versus one of the alternative agents.
Thus, we sought to develop and externally validate a model to predict prolonged dose titration in
patients initiating warfarin therapy.
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METHODS
Overview. We derived a prediction model for whether a patient initiating warfarin achieved
maintenance dose within the first 12 weeks of attempted therapy, using a Cox proportional
hazards model. We then validated this model in an external prospective cohort of patients
initiating warfarin. All analyses were performed in R 3.1.0 [R Development Core Team, 2014].

Derivation cohort. We derived the prediction model using the IN-RANGE cohort, a large
prospective cohort of warfarin initiation that has been used to study the clinical and genetic
predictors of warfarin maintenance dose and adherence [Kealey et al., 2007; Kimmel et al., 2007,
2008; Parker et al., 2007; Platt et al., 2008, 2010; Schelleman et al., 2010, 2007; Schelleman,
Chen, et al., 2008]. Participants were recruited from specialty anticoagulation clinics at the
Hospital of the University of Pennsylvania (HUP), the Philadelphia Veterans Affairs Medical
Center (PVAMC), and Hershey Medical Center. Institutional review board approval was obtained
at all three sites, and all study participants provided written informed consent. Exclusion criteria
were kept to a minimum to ensure patient generalizability. Specific exclusion criteria included
being under 21 years old, being unwilling or unable to provide consent, having an abnormal INR
prior to starting warfarin or heparin therapy, or the presence of antiphospholipid antibodies.
Participants were enrolled between April 2002 and February 2006. All participants in the original
IN-RANGE cohort (N = 390) were included as part of the derivation cohort for the current study.

Validation cohort. Once the prediction model was developed, it was then validated in an external
cohort. The cohort used for validation was the IN-RANGE2 cohort, which was designed as a
follow-up cohort to the original IN-RANGE cohort, with similar data collection methods.
Participants were recruited from specialty anticoagulation clinics at HUP, PVAMC, and Johns
Hopkins University (JHU). Institutional review board approval was obtained at all three sites, and
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all study participants provided written informed consent. Exclusion criteria were purposefully
kept similar to the original IN-RANGE cohort, with the only difference being that individuals
who were neither Caucasian nor African American (about 3% of the original cohort) were
excluded from the IN-RANGE2 study and that the presence of antiphospholipid antibodies was
dropped as an exclusion criterion for the IN-RANGE2 study. Participants were enrolled between
October 2009 and August 2013. All participants with data available as of August 2014 (N = 663)
were included in the validation cohort for the current study.

Primary outcome. The primary outcome was a prolonged dose-titration phase, defined as whether
an individual achieved maintenance dose within 12 weeks of attempted warfarin therapy. The 12
week cut-off was selected as a clinically meaningful cut-off, as the first 3 months of warfarin
therapy have been shown to be especially high risk for patients [Fihn et al., 1993], and some
warfarin indications, such as venous thromboembolism with transient risk factors, often only
require a 3 month course of therapy [Agnelli & Becattini, 2008]. Additionally, we used a
dichotomous rather than continuous outcome, such as time to maintenance dose, to make it easier
for clinicians to incorporate model predictions into their decision-making process. Achievement
of maintenance dose was defined as having two consecutive INRs within the therapeutic range, at
the same warfarin dose, at least one week apart. Use of this definition allowed for the outcome to
be defined the same across both the derivation and validation cohorts. Additionally, the time of
maintenance dose achievement was taken as the number of days from warfarin initiation to the
first maintenance dose-defining visit in days. Reaching maintenance dose within 4 and 8 weeks
were also considered as outcomes in secondary analyses.

Candidate predictors. A total of 28 candidate baseline social and clinical factors were considered
for inclusion in the primary prediction model, shown in Table 3.1. Most of these candidate
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Table 3.1. Candidate baseline social and clinical predictors and their specifications.
Candidate Predictor
Social
Self-reported race
Gender
Marital status
Employment status
Education statusa
Insurance status
Number of alcoholic
drinks per weeka
Current smoking status
Self-reported general
health status
No. hospitalizations
in past 12 months
No. doctor’s visits
in past 12 months
Had difficulty receiving
health care in the past
12 months
Clinical
Age (years) at baseline visit
Body Mass Indexa
Previous use of warfarina
Warfarin indication
Number of interacting
medications being used
at baselinea

Specification
Binary (0 = not African American; 1 = African American)
Binary (0 = male; 1 = female)
Categorical (1 = married (ref); 2 = separated/divorced;
3 = widowed; 4 = never married)
Categorical (1 = working; 2 = unemployed/disabled;
3 = retired (ref))
Binary (0 = more than high school; 1 = high school or less)
Categorical (1 = private (ref); 2 = any VA/Medicare only;
3 = Medicaid/no insurance)
Binary (0 = 0 drinks; 1 = 1 or more drinks)
Binary (0 = not current smoker; 1 = current smoker)
Categorical (1 = excellent/very good (ref); 2 = good;
3 = fair/poor)
Categorical (1 = 0 visits (ref); 2 = 1–2 visits; 3 = 3 or more
visits)
Categorical (1 = 0–3 visits; 2 = 4–12 visits (ref); 3 = 13 or
more visits)
Binary (0 = no; 1 = yes)

Continuous (linear)
Continuous (linear)
Binary (0 = no; 1 = yes)
Categorical (1 = atrial fibrillation/atrial flutter (ref); 2 = post
deep vein thrombosis/pulmonary embolism; 3 = other)
Binary (0 = 0–1 medications; 1 = 2 or more medications)

Amiodarone use at baselinea Binary (0 = no; 1 = yes)
Statin use at baseline
Binary (0 = no; 1 = yes)
CHADS2 score
Categorical (1 = 0 (ref); 2 = 1; 3 = 2 or higher)
History of peptic ulcer
Binary (0 = no; 1 = yes)
disease or gastritis
History of stroke
Binary (0 = no; 1 = yes)
History of cancer
Binary (0 = no; 1 = yes)
History of hypertension
Binary (0 = no; 1 = yes)
History of diabetesa
Binary (0 = no; 1 = yes)
History of arrhythmia
Binary (0 = no; 1 = yes)
History of congestive
Binary (0 = no; 1 = yes)
heart failure
History of myocardial
Binary (0 = no; 1 = yes)
infarctiona
a
These variables were excluded from the model via a univariable screen, described in the
Methods section.
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predictors have been previously associated with other warfarin-related outcomes, such as warfarin
maintenance dose requirement [Gage et al., 2008; Klein et al., 2009], poor warfarin adherence
[Arnsten et al., 1997; Platt et al., 2008, 2010], discontinuation of warfarin [Bushnell et al., 2011;
Fang et al., 2010; Song, Sander, Varker, & Amin, 2012], percent time in therapeutic range
[Hylek, Heiman, Skates, Sheehan, & Singer, 1998; Kimmel et al., 2007; Wieloch et al., 2011],
and risk of bleeding events [Beyth et al., 1998; Gage et al., 2006; Lip et al., 2011; Shireman et al.,
2006]. Additionally, after constructing a model from baseline social and clinical factors, we were
interested in whether inclusion of genetic factors could improve model prediction. For this
analysis, we added genetic variants in CYP2C9 (rs1799853 and rs1057910) and VKORC1
(rs9923231), specified in a binary fashion as having at least one variant in the given gene, to the
model. These variants were chosen because they have most consistently demonstrated a large
association with warfarin maintenance dose in the literature, and are used in the major
pharmacogenetic dosing algorithms [Gage et al., 2008; Kimmel et al., 2013; Klein et al., 2009].

Choice of statistical model. Because approximately 11% of the derivation cohort was censored
prior to 12 weeks of attempted warfarin therapy, we needed to use a statistical model that could
accommodate censoring. As a result, we used a Cox proportional hazards model with time from
initiation of warfarin to the achievement of maintenance dose or censoring in days as the
outcome. The probability of prolonged dose titration was, thus, the conditional probability of
survival predicted from this model at the time-point of interest, 12 weeks of attempted warfarin
therapy. Because we were not interested in modeling follow-up time after this cut-off point, all
individuals who had not reached maintenance dose by 12 weeks were artificially censored at this
time.
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Univariable screen. To reduce overall computing time for our analyses to manageable levels, we
chose to perform a univariable screen to reduce the number of candidate predictors from the
initial 28 to 20, which was determined a priori to be an appropriate number of candidate
variables, given computational constraints. For each candidate predictor, we constructed a
univariable Cox proportional hazards model of the time from initiation of warfarin to the
achievement of maintenance dose or censoring. We then estimated the time-dependent area under
the ROC curve (AUC) at 12 weeks of follow-up using 10-fold cross-validation for each model.
The 20 variables with the best time-dependent AUCs in the univariable screen were selected for
inclusion in the modified best subsets variable selection algorithm, described below.

Time-dependent AUC. The time-dependent AUC—developed by Heagerty, et al. [Heagerty,
Lumley, & Pepe, 2000]—differs from the standard AUC because it accommodates censoring, and
it differs from the commonly used C-index because it assesses model discrimination at a single
point in time, rather than over the total duration of follow-up. The time-dependent AUC can thus
be interpreted as the probability that a randomly selected individual who has experienced the
failure event by time t will have a higher predicted probability of failure at time t than a randomly
selected individual who has not experienced the failure event by time t. This statistic is estimated
by integrating the time-dependent sensitivity and specificity across all possible cut-off values for
the linear predictor derived from the model. Because cross-validation was used during the model
development process, the linear predictor was calculated in the data subset that was withheld
during estimation of the Cox model, repeated for all data subsets (e.g. 10 times for 10-fold crossvalidation). When the model was assessed in the external validation cohort, the linear predictors
in that cohort were used without cross-validation.

40

Because individuals may be censored prior to time t, the values for time-dependent sensitivity and
specificity need to be estimated from the data. As recommended by Heagerty, et al., we used a
nearest neighbor estimator—which is essentially a weighted Kaplan-Meier estimator based on a
nearest neighbor kernel function, developed by Akritas [Akritas, 1994]—which allows for
monotonicity of sensitivity and specificity and for the censoring process to depend on the
predictive marker of interest. This estimator is dependent on a smoothing parameter, , where 2
represents the percentage of observations that are included in an individual observation’s
neighborhood; in our case, we chose the default value of

= 0.025. The “survivalROC” package

in R was used to facilitate these calculations [Heagerty & Saha-Chaudhuri, 2013].

Variable selection algorithm. Variable selection was conducted using a modified best subsets
algorithm [Miller, 2002]. This algorithm was designed to optimize model discrimination, or how
well a model distinguishes between those who did and did not experience the outcome (in this
case, those who had a prolonged vs non-prolonged dose-titration phase, respectively). We
calculated the time-dependent AUC at 12 weeks using 10-fold cross-validation for all possible
combinations of the candidate predictors up to 10 predictor variables in length (616,665
combinations) to reduce our chances of selecting a combination based on overfitting. Because we
felt that leave-one-out cross-validation (LOOCV)—in which one person at a time is removed
from the dataset to build the model and then used for model testing, for all individuals in the
dataset—was a better estimate of external validation than 10-fold cross-validation [Hastie,
Tibshirani, & Friedman, 2009], we opted to estimate the time-dependent AUC using LOOCV in
the 1,000 best models based on 10-fold cross-validation for each subset size (8,210
combinations). The combination of predictors that led to the highest time-dependent AUC using
LOOCV was then selected as our final prediction model.
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In short, our algorithm was designed to select the combination of candidate variables with the
best estimated LOOCV time-dependent AUC. Furthermore, this strategy had the advantage of
choosing the best subset based on LOOCV, without the nearly 40-fold increase in computing time
that would be required by calculating the time-dependent AUC using LOOCV in all possible
combinations of predictors. A sensitivity analysis showed that this algorithm selected the exact
same best combination of predictor variables as using LOOCV on all possible combinations up to
6 predictor variables in length. Once selected, prediction model variables were then inspected
graphically to ensure proper functional form, and all coefficients were examined to ensure that
the direction of effect reported by the model was consistent with the available literature.

Linear shrinkage factor. Because regression coefficients are often overestimated in small
samples, prediction models will often show better calibration for out-of-sample predictions when
coefficients are shrunk toward zero [Van Houwelingen & Le Cessie, 1990]. Thus, we sought to
apply a linear shrinkage factor—which has been shown to perform well in small samples for
improving model calibration, without sacrificing model discrimination [Steyerberg, Eijkemans,
Harrell, & Habbema, 2000]—to our final prediction model. To estimate the shrinkage factor, we
fit the model in a bootstrap sample of the derivation cohort. We then calculated the linear
predictors of the individuals in the derivation cohort using the model coefficients from the
bootstrap sample. The slope of the actual observed outcomes regressed on these bootstrapped
linear predictors could then be used as an estimate of the shrinkage factor. To form a stable
estimate of the shrinkage factor, we calculated the mean slope over 1,000 bootstrap replications.
All of the original model coefficients were then multiplied by this shrinkage factor to produce the
final shrunk coefficients, which were used for generating predictions in the external validation
cohort. Because all of the coefficients are being multiplied by the same factor, the rank order of
individual predictions is preserved and model discrimination is not affected by shrinkage.
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In order to ensure that shrinkage was toward the overall mean and not toward the overall
reference category, continuous variables needed to be centered at the mean and categorical
variables had to be coded using simple contrasts. In this contrast method, reference groups were
coded as

, while non-reference categories were coded as (

)

, where

is the number

of categories. In this contrast method, the reference category of 0 is equivalent to the overall
mean of the sample in which the model is being fit. Note that the difference between the reference
and non-reference categories is still 1; thus, the interpretation of coefficients in this contrast
method is identical to the more common dummy coding for categorical variables (i.e. 0 for
reference and 1 for non-reference categories).

Model assessment and validation. The final prediction model was then assessed in a separate
validation cohort, described above. Predictions from the model were used to estimate the timedependent AUC as the primary measure of model discrimination in the validation dataset.
Additionally, genetic predictors were added to the model to see if there was a significant
difference in the AUC between the two models. The integrated discrimination improvement (IDI)
between the two models was also estimated [Liu, Kapadia, & Etzel, 2010]. We also assessed the
calibration of the prediction model using calibration plots. Finally, we examined the clinical
utility of the prediction model using decision curves and plots of the relative utility of the model
versus the risk threshold [Baker, Cook, & Vickers, 2009; Baker, 2009; Vickers, Cronin, Elkin, &
Gonen, 2008; Vickers & Elkin, 2006]. Confidence intervals for all estimates were generated using
the 2.5th and 97.5th percentiles of estimates in 1,000 bootstrap replications.

The methods for determining clinical utility rely on the concept of the risk threshold, which is the
probability of the outcome at which the clinician is indifferent about which treatment strategy to
use; in other words, it is the probability at which the costs of false positive and false negative
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mistakes are equal [Pauker & Kassirer, 1975]. Furthermore, the consequences of basing a clinical
decision on the predicted probability from a risk prediction model can be estimated as a function
of the risk threshold. While the exact threshold will vary depending on the value that physicians
and patients place on certain outcomes, the metric can be used to determine the clinical usefulness
of a given model under a range of possible thresholds. For our prediction model, given broadly
similar safety and efficacy profiles for warfarin and the alternative anticoagulants (with the
possible exception of apixaban) [O’Dell, Igawa, & Hsin, 2012; Rollins, Silva, Donovan, &
Kanaan, 2014], the risk threshold for a given patient would likely depend primarily on his or her
relative costs of INR monitoring on warfarin versus the out-of-pocket financial costs of the
alternative anticoagulant agents. In this scheme, patients that are more burdened by financial
costs would have a risk threshold above 0.5, while those that are more burdened by INR
monitoring would have a risk threshold below 0.5.

Decision curves plot the net benefit of various treatment strategies versus the risk threshold,
where the net benefit is equal to the true positive rate minus the false positive rate, weighted as a
function of the risk threshold [Vickers & Elkin, 2006]. In this case, the net benefit is calculated
relative to the strategy of using standard warfarin therapy in all patients. The curve shows the
values of the risk threshold where using the prediction model would be expected to provide a net
benefit above the strategies of using the same treatment in every patient. Relative utility is a
related measure of the usefulness of a prediction model that is essentially a rescaling of the net
benefit, and it can be interpreted as the net benefit of the prediction model, compared to using the
same treatment strategy in all patients, as a fraction of the net benefit of perfect prediction [Baker
et al., 2009]. A relative utility of 1 indicates that the model performs as well as perfect prediction,
while negative values indicate that the model is worse than using the same strategy in everyone.
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RESULTS
The characteristics of the derivation and validation cohorts are shown in Table 3.2. The overall
prevalence of prolonged dose-titration was 30% in the derivation cohort and 38% in the
validation cohort. The variable selection algorithm found that the best LOOCV time-dependent
AUC was in a model with the following five variables: warfarin indication, insurance status,
number of doctor’s visits in the previous year, current smoking status, and history of heart failure.
The LOOCV time-dependent AUC in this model was estimated as 0.66 (95% CI 0.60, 0.74). A
comparison of this model to the other top performing models with different numbers of predictor
variables, as measured with cross-validation, suggested that using cross-validation successfully
avoided complex models that were more accurate merely because of having extra degrees of
freedom (Figure 3.1). The shrinkage factor based on 1,000 bootstrap replications was estimated to
be about 0.82, indicating a moderate degree of overfitting in the original model. Coefficients from
the final prediction model, after applying the linear shrinkage factor, are shown in Table 3.3.

When tested in the validation cohort, the AUC of the prediction model at 12 weeks was 0.59
(95% CI 0.54, 0.64). The ROC curve for this model is shown in Figure 3.2. The AUC of the
model at 8 weeks was 0.57 (95% CI 0.53, 0.62) and at 4 weeks was 0.57 (95% CI 0.52, 0.62).
The calibration of the main model was examined by comparing predicted probabilities to
observed frequencies across risk deciles (Figure 3.3); the Hosmer-Lemeshow test for goodness of
fit did not show significantly poor model calibration (P = 0.73). Addition of genetic factors did
not significantly change the AUC at 12 weeks (P > 0.99), with the point estimate remaining
unchanged at 0.59 (95% CI 0.54, 0.64). A comparison of the ROC curves for the models with and
without genetic factors is shown in Figure 3.4. The calibration of the genetic model, however,
seemed worse than the main model, though the level of miscalibration was not significantly
worse than what would be expected due to chance, using the Hosmer- Lemeshow test (P = 0.06).
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Table 3.2. Characteristics of the derivation and validation cohorts.
Variable

Derivation cohort
(N = 390)a

Validation cohort
(N = 663)a

P-valueb

135 (20)
131 (20)
219 (33)
116 (18)
60 (9)
250 (38)
466 (71)

< 0.001

186 (28)
189 (29)
280 (43)
461 (70)
190 (29)
98 (15)

0.11

< 0.001
0.71
0.01

141 (21)

0.65

214 (32)
343 (52)
105 (16)
209 (32)

< 0.001

275 (42)
235 (36)
148 (22)

< 0.001

276 (42)
272 (41)
110 (17)

< 0.001

167 (25)
49 (7)
192 (29)
251 (38)

< 0.001

228 (41)
45 (8)
282 (51)

< 0.001

263 (40)
198 (30)
—
202 (30)

< 0.001

Age
< 45
65 (17)
45 – 55
74 (19)
55 – 65
103 (26)
65 – 75
83 (21)
75+
65 (17)
Female gender
119 (31)
African American race
174 (45)
Body Mass Index
< 25
122 (32)
25 – 30
125 (32)
> 30
140 (36)
History of hypertension
192 (49)
History of diabetes
107 (27)
History of peptic ulcer
36 (9)
disease
History of heart failure
78 (20)
Warfarin indication
AFib/AFlutter
188 (48)
DVT/PE
116 (30)
Other
86 (22)
Previously used warfarin
96 (25)
Smoking status
Never
141 (36)
Past
185 (47)
Current
64 (16)
Insurance status
Private
215 (56)
VA/Medicare/Other
124 (32)
Medicaid/None
45 (12)
Employment status:
Working
128 (33)
Unemployed
34 (9)
Retired
143 (37)
Disabled
81 (21)
Annual income:
< $15,000
109 (33)
$15,000 - $20,000
99 (30)
> $20,000
122 (37)
Site:
HUP
184 (47)
PVAMC
137 (35)
Hershey
69 (18)
JHU
—
a
All values are reported as N (%).
b
P-values are based on the chi-square test.
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0.02
< 0.001

0.02

Figure 3.1. Comparison of best prediction models by number of predictor variables in the model.
Prediction models compared by the time-dependent AUC at 12 weeks, as estimated by leave-one-out crossvalidation (LOOCV).
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Table 3.3. Final prediction model coefficients.
Predictor variable
Shrunk coefficienta,b
Warfarin indication
AFib/Aflutter
—
DVT/PE
-0.47
Other
-0.33
Insurance status
Private insurance
—
VA/Medicare
-0.14
Medicaid/None
-0.42
Number MD visits in previous year
<4
-0.29
4-12
—
>12
-0.23
Current smoker
-0.17
History of heart failure
-0.21
a
Coefficients were multiplied by a linear shrinkage factor,
equal to about 0.82, based on 1,000 bootstrap replications.
b
Negative coefficients indicate a higher probability of
prolonged dose titration.

Figure 3.2. ROC curve for the prediction model as tested in the validation dataset.
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Figure 3.3. Predicted probability vs observed frequency of prolonged dose titration by risk decile.

Figure 3.4. Comparison of ROC curves for the prediction models with and without the addition of genetic
factors.
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The integrated discrimination improvement from adding genetic factors to the model was
estimated as 0.01 (0.00, 0.02), which is equivalent to a 7% increase in model discrimination over
the model without genetic factors.

To examine the clinical utility of the prediction model, the sensitivity, specificity, and positive
and negative predictive values for various risk thresholds were calculated (Table 3.4). Similarly,
Figure 3.5 shows the relationship between the positive and negative predictive values and the
proportion that are classified as positive across the full range of risk thresholds. Predicted
probabilities of prolonged dose titration in the validation cohort ranged from about 16% to 63%;
thus, predictive values only varied over this range. The relative utility of the model—which can
be understood as the net benefit of the current model, compared to not using a prediction model,
as a fraction of the net benefit of perfect prediction—across the full range of risk thresholds is
shown in Figure 3.6. The maximum relative utility observed was 9.4%, and the relative utility
was negative for the risk threshold range of 48% to 62%. Comparisons of relative utility and
decision curves for the models with and without genetic factors are shown in Figures 3.7 and 3.8,
respectively.

We also examined site-specific differences in model performance in post-hoc analyses.
Differences in the characteristics of the derivation and validation cohorts at HUP and PVAMC
are shown in Table 3.5. The time-dependent AUC at 12 weeks was 0.60 (95% CI 0.51, 0.67) at
HUP, 0.55 (95% CI 0.45, 0.63) at PVAMC, and 0.61 (95% CI 0.53, 0.69) at JHU. Finally, the
observed frequency of prolonged dose titration was 32%, 34%, and 48% at HUP, PVAMC, and
JHU, respectively; predicted probabilities of the outcome at the respective sites, however, were
37%, 39%, and 38%.

50

Table 3.4. Model characteristics at various risk thresholds.
Positive
Negative
Proportion
Predictive
Predictive
Predicted
Value
Value
Positive
10%
0.11
1.00
0.00
0.37
—
1.00
20%
0.25
0.99
0.03
0.38
0.87
0.98
30%
0.43
0.83
0.28
0.41
0.74
0.76
40%
0.67
0.52
0.58
0.43
0.67
0.46
50%
1
0.19
0.86
0.44
0.64
0.16
60%
1.5
0.03
0.99
0.57
0.63
0.02
70%
2.33
0.00
1.00
—
0.63
0.00
a
The risk threshold refers to the cut-off probability, where one classifies individuals as positive when
predicted to be above the cut-off or negative when predicted to be below the cut-off. In this case,
being “positive” refers to having a high probability of prolonged dose titration on warfarin,
potentially leading a physician to choose an alternative therapy.
b
CFP/CFN refers to the ratio of the costs of false positive and false negative mistakes that are implied
by the risk threshold, according to decision theory.
Risk thresholda

CFP/CFNb

Sensitivity

Specificity

Figure 3.5. Positive predictive value, negative predictive value, and proportion of patients classified as
positive across the range of values for the risk threshold. Individuals with a predicted probability of
prolonged dose titration are classified as positive. The absence of a curve in a given region indicates that
the measure is undefined in that region; for instance, positive predictive value is undefined when no
patients are classified as positive.
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Figure 3.6. Relative utility of the prediction model across the full range of risk thresholds.

Figure 3.7. Comparison of relative utility curves in prediction models with and without genetic factors.
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Figure 3.8. Decision curve of prediction models with and without genetic factors. In this case, the decision
curve plots the net benefit of the prediction model compared to the strategy of using standard warfarin
treatment in everyone, across the full range of values for the risk threshold. The strategy of using standard
warfarin treatment in everyone is shown with the solid black line, while the strategy of using an
alternative therapy in everyone is shown with the dashed black line. The net benefit of the strategies of
using standard warfarin therapy in everyone and using an alternative therapy in everyone intersects when
the risk threshold is equal to the prevalence of the outcome in the overall population. Note that the curve
for the all on alternative therapy strategy continues downward beyond the edge of the figure.
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Table 3.5. Characteristics of the derivation and validation cohorts by site.
Variable

HUPa
Derivationb Validationb
(N = 184)
(N = 263)

PVAMCa
Derivationb Validationb
(N = 137)
(N = 198)

Age
< 45
51 (28)
75 (29)
12 (9)
7 (4)
45 – 55
39 (21)
61 (23)
23 (17)
28 (14)
55 – 65
35 (19)
62 (24)
57 (42)
96 (48)
65 – 75
35 (19)
41 (16)
28 (20)
45 (23)
75+
24 (13)
23 (9)
17 (12)
22 (11)
Female gender
89 (48)
136 (52)
5 (4)
9 (5)
African American race
103 (56)
188 (71)
70 (51)
147 (74)
Body Mass Index
< 25
63 (34)
66 (25)
41 (30)
62 (31)
25 – 30
62 (34)
77 (30)
36 (26)
57 (29)
> 30
59 (32)
117 (45)
59 (43)
79 (40)
History of hypertension
87 (47)
170 (65)
66 (48)
151 (76)
History of diabetes
40 (22)
68 (26)
50 (36)
71 (36)
History of peptic ulcer disease
16 (9)
26 (10)
17 (12)
9 (5)
History of heart failure
31 (17)
58 (22)
34 (25)
40 (20)
Warfarin indication
AFib/AFlutter
68 (37)
81 (31)
70 (51)
87 (44)
DVT/PE
73 (40)
131 (50)
40 (29)
86 (44)
Other
43 (23)
51 (19)
27 (20)
24 (12)
Previously used warfarin
47 (26)
75 (29)
40 (29)
72 (36)
Smoking status
Never
90 (49)
130 (50)
19 (14)
37 (19)
Past
73 (40)
87 (34)
79 (58)
92 (46)
Current
21 (11)
42 (16)
39 (28)
69 (35)
Insurance status
Private
151 (84)
162 (63)
6 (4)
10 (5)
VA/Medicare/Other
7 (4)
43 (17)
107 (79)
154 (78)
Medicaid/None
21 (12)
54 (21)
23 (17)
34 (17)
Employment status:
Working
79 (43)
78 (30)
32 (24)
18 (9)
Unemployed
17 (9)
22 (8)
17 (13)
12 (6)
Retired
49 (27)
62 (24)
49 (36)
91 (46)
Disabled
39 (21)
99 (38)
37 (27)
77 (39)
Annual income:
< $15,000
48 (29)
90 (37)
41 (38)
95 (49)
$15,000 - $20,000
45 (27)
18 (7)
48 (45)
18 (9)
> $20,000
72 (44)
137 (56)
18 (17)
79 (41)
a
Sites were limited to those that were present in both derivation and validation cohorts.
b
All values are reported as N (%).
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DISCUSSION
Overview. In this study, we sought to develop a model to predict whether a patient starting
warfarin would have a prolonged dose-titration phase, and then test the model in an external
validation cohort. Given the availability of less burdensome but more expensive alternative oral
anticoagulant agents, being able to predict prolonged dose titration could help patients and
clinicians decide whether to use warfarin or one of the alternative agents. However, the prediction
model we developed failed to validate in an external cohort, with an AUC of 0.59 (95% CI 0.54,
0.64). Thus, our results suggest that it will be difficult for clinicians to predict prolonged dose
titration in patients starting warfarin, at least using traditional social, clinical, and genetic
predictors.

Model development. The final model contained five variables: warfarin indication, insurance
status, number of doctor’s visits in the previous year, current smoking status, and history of heart
failure. This model performed moderately well in the derivation cohort, with a time-dependent
AUC at 12 weeks, as measured by LOOCV, of 0.66 (95% CI 0.60, 0.74). Furthermore, only a
moderate amount of shrinkage was needed to improve model calibration, with a linear shrinkage
factor of 0.82. Finally, the association between the selected predictor variables and the outcome
seemed to be quite stable, as these predictors were seen in the best models across the full range of
subset sizes (Figure 3.1).

Model validation. The model performed much worse when tested in the external validation
cohort, however. The time-dependent AUC at 12 weeks was only 0.59 (95% CI 0.54, 0.64) when
validated externally. Model performance did not improve for the secondary outcomes of reaching
maintenance doses within 4 and 8 weeks, indicating that the model’s limited ability to
discriminate was not unique to a specific time point cut-off. Although the variable selection
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algorithm was designed to optimize model discrimination, the model appeared to be reasonably
well calibrated in the overall validation cohort, with a non-significant Hosmer-Lemeshow
calibration test (P = 0.73). This result suggests that our use of a linear shrinkage factor was
largely successful in improving model calibration. However, we believe that model
discrimination is the best way to determine the clinical utility of this prediction model, because it
would allow clinicians to distinguish between patients at higher risk for prolonged dose titration
on warfarin from those at lower risk.

The addition of genetic variants did not improve the performance of the model, with no
improvement in the time-dependent AUC observed (P > 0.99). Similarly, the IDI was also poor at
0.01 (95% CI 0.00, 0.02), although it was technically a statistically significant improvement in
discrimination. The IDI as a test statistic is known to have problems with type I error, especially
as it approaches zero [Kerr, McClelland, Brown, & Lumley, 2011; Pepe, Feng, & Gu, 2008], so
this finding of statistical significance should be viewed with skepticism in the context of the rest
of our results. Overall, the lack of improvement in prediction from adding genetic factors is
consistent with recent clinical trial evidence showing that inclusion of genetic factors in dose
prediction models did not lead to significant improvement in clinical outcomes, such as percent
time in therapeutic range or time to maintenance dose, over purely clinical dose prediction
algorithms [Kimmel et al., 2013].

Differences between derivation and validation cohorts. One reason for the failure of the model to
validate is likely the substantial differences between the derivation and validation cohorts, as
shown in Table 3.2. Compared with the derivation cohort, the validation cohort was younger,
more African American, more obese, more under-insured, and more disabled, among other
differences. These differences are likely reflected in the fact that the prevalence of prolonged
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dose titration was higher in the validation cohort at 38%, compared to 30% in the derivation
cohort. Part of these differences might reflect discrepancies in populations at different sites; for
example, the anticoagulation clinic at Johns Hopkins draws from a much more urban African
American population than the clinic at Hershey Medical Center. However, there are also
substantial differences between the derivation and validation cohorts at the sites that were the
same for both cohorts, including the proportion of individuals who are African American, the
prevalence of hypertension, the prevalence of different warfarin indications, and the proportion of
individuals on disability (Table 3.5). These differences can potentially be attributed to random
fluctuations, to changes in the warfarin population or outcomes over time, to differences in
practice patterns over time, to differences in those willing to participate, or to changes in
recruitment strategies between the two studies. For instance, a decrease in the proportion of
patients with atrial fibrillation as their warfarin indication could be related to some of these
patients being treated with alternative anticoagulants, which were first approved for that
indication. By contrast, the increase in the proportion of patients who were African American at
these sites likely reflects recruitment strategies that were designed to increase the enrollment of
this group in the validation cohort.

These differences across sites are also reflected by varying performance of the prediction model
across sites. For instance, the time-dependent AUC was not significantly better than chance at
PVAMC, while it was better at the other sites. Similarly, the model could not account for the
substantial differences in baseline risk that was observed at the three sites, with the prevalence of
prolonged dose titration varying from 32% to 48%. Moreover, a post-hoc analysis where a
prediction model was developed and tested using the same algorithm in the sites that were present
in both derivation and validation cohorts showed no improvement in model performance (AUC =
0.58; 95% CI 0.51, 0.64), confirming the changes in these same sites over time. Similarly, in
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another post-hoc analysis, performance of the same model development algorithm in the
validation cohort led to the inclusion of some different variables in the model—variables selected
were age, BMI, warfarin indication, insurance status, previous warfarin use, history of heart
failure, and history of arrhythmia—suggesting that the important predictors of prolonged dose
titration might vary across sites. This model did not perform very well on cross-validation
(LOOCV AUC = 0.62; 95% CI 0.58, 0.69), suggesting that it also would not perform well on
external validation. It should also be emphasized that the broader differences among sites where
patients receive warfarin in the clinical community would be expected to be much larger than the
differences between our derivation and validation cohort; thus, the performance of the model in
clinical practice could be expected to be even worse.

Clinical utility of the prediction model. Attempts to quantify the clinical impact of the prediction
model were consistent with our primary results. While the negative predictive value of the model
for the lowest range of predicted values (< 20% probability of prolonged dose titration) was
reasonably good at 0.87, only 2% of patients in the validation cohort actually fall into this
category (Table 3.4). Both positive and negative predictive values were fairly poor at cut-offs that
were more commonly observed in our cohort. This drop-off in performance may result from
incorrectly ranking individuals in the middle of the probability distribution, which can be seen
when plotting the observed vs predicted probabilities by risk decile (Figure 3.4).

As shown in Figure 3.6, the relative utility of the current model is limited, with a maximum value
of about 0.09 near the prevalence of the outcome. Additionally, the relative utility is negative for
risk thresholds above 0.47, meaning that it is better to use standard warfarin therapy for all
patients with high risk thresholds. This impression is confirmed by the related decision curve,
which shows that the curves representing the net benefit of the prediction models are not
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substantially higher than the curves for the strategies of using the same treatment in everyone for
any risk threshold region (Figure 3.8). While the prediction model is unlikely to be useful
clinically even in the regions where the relative utility is strictly positive, examination of the risk
threshold can still be useful for clinicians. Knowing that the overall prevalence of prolonged dose
titration is about 38%, a discussion of the relative importance financial and monitoring burdens
with patients can help determine whether treatment with warfarin or an alternative agent is
optimal in a given situation. For instance, if a given patient feels that the financial costs of
alternative anticoagulant agents are worse than the monitoring burden of warfarin therapy, then
his or her individual risk threshold would be above 50%. Since this threshold is greater than the
38% prevalence of prolonged dose titration, it would be optimal to begin standard warfarin
therapy in this patient.

Importance of external validation. This study confirms the importance of using external
validation when developing clinical risk prediction models. Given its importance, external
validation is performed surprisingly infrequently, with recent evidence suggesting that only 25%
of published research on new prediction models includes an external validation [Siontis,
Tzoulaki, Castaldi, & Ioannidis, 2014]. Especially for complex, multifactorial outcomes like
prolonged dose titration for patients starting warfarin, overall prevalence and the importance of
different predictors are likely to vary substantially across clinical sites, and even change over
time. While statistical methods such as cross-validation can help, external validation remains the
gold standard for determining whether a prediction model will be useful in clinical practice.

Conclusions. In conclusion, our prediction model for prolonged dose titration in patients starting
warfarin is unlikely to be useful in clinical practice. Moreover, we suspect that this outcome and
others like it will be difficult to predict using traditional clinical or genetic risk factors, as their
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relationship to the outcome will likely vary substantially across clinical sites. More accurate
prediction of prolonged dose titration will likely require researchers to better define and measure
the social, behavioral, and access-related factors that are probably more directly related to the
outcome. In the absence of risk prediction, clinicians should consider the relative importance of
monitoring and financial burdens for their patients when deciding which type of anticoagulation
therapy to begin.
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CHAPTER 4. IMPROVING CLINICAL PREDICTION MODEL
TRANSPORTABILITY WITH SEQUENTIAL UPDATING OF MIXEDEFFECTS MODELS

Brian S Finkelman, Benjamin French, and Stephen E Kimmel

ABSTRACT
Clinical prediction models often fail to generalize across clinical sites outside of those in which
the model was derived, and they tend to lose their accuracy over time. These problems have been
categorized under the umbrella term of poor model transportability. We propose a general
strategy of sequential updating of mixed-effects models as a mechanism to overcome the problem
of poor transportability. We examine the potential gains in prediction accuracy for this strategy
through a simulation study in which poor transportability is modeled as clinic-specific differences
in the prevalence of the outcome and the association between predictors and the outcome. We
then test whether the sequential model updating approach is robust to several types of model
misspecification.

BACKGROUND
Clinical prediction model transportability. It is well established that clinical prediction models
often suffer from the problem of the poor generalizability [König, Malley, Weimar, Diener, &
Ziegler, 2007]. In other words, models that perform well in the datasets in which they were
derived, measured either by model calibration or discrimination, often perform worse when tested
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in other settings. Generalizability of prediction models has been previously described as
encompassing two major components: reproducibility and transportability [Justice et al., 1999].
Reproducibility of prediction models can be thought of as the ability of the model to perform well
in repeated samples from the same population as the one that yielded the original derivation
sample, while transportability refers to the ability of the model to perform well in samples drawn
from different but plausibly related populations to the one that yielded the original derivation
samples. These plausibly related populations could differ from the original population based on
changes over time, geography, clinical setting, and definitions of predictors or outcomes, among
other things.

Many statistical methods have been developed to help address the problem of model
reproducibility, such as Bayesian model averaging [Hoeting et al., 1999], bootstrap aggregation
or bagging [Breiman, 1996], and a variety of methods for cross-validation [Borra & Di Ciaccio,
2010]. Broadly speaking, these methods tend to address the problem of model overfitting.
However, poor transportability of a prediction model often occurs because of a problem of
underfitting rather than overfitting [Justice et al., 1999]. Underfitting occurs when important
predictors are either unknown, misspecified, or not included in the original model, and model
performance degrades when tested in new populations with a different conditional prevalence of
those predictors. As a result, it is much more difficult to find statistical solutions to problems of
transportability using the derivation sample, because by definition, the model would need to be
tested on a sample with a different empirical distribution from the derivation sample in order to
determine its transportability.

Utility of clinical prediction models is hampered by concerns about poor transportability. Despite
the adoption of prediction models in clinical practice, there are often major concerns about model
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generalizability and transportability in many clinical scenarios. For instance, the American Heart
Association (AHA) and the American College of Cardiology (ACC) released updated cholesterol
management guidelines in November 2013 that were heavily based on individuals’ predicted 10year risk of cardiovascular events [Stone et al., 2014]. These guidelines drew almost immediate
criticism because of concern about over-prediction of risk related to the particular cohorts used to
develop the prediction model [Ridker & Cook, 2013]. Specific examples of validated prediction
models failing to generalize to different populations have been documented, as well. For example,
the EuroSCORE model, which was developed in European populations to predict 30-day
mortality in patients undergoing cardiac surgery, failed to generalize to Australian surgical
patients [Yap et al., 2006], and, even with the European population, proved inaccurate over time,
over-predicting risk in contemporary practice [Hickey et al., 2013]. In another example, a clinical
prediction rule for predicting deep vein thrombosis (DVT) performed well in the secondary
referral patient population in which it was developed, but failed to generalize to a primary care
setting [Oudega et al., 2005]. Furthermore, this problem is likely even more widespread than what
has been directly documented in the literature because of the many clinical outcomes that are
known to vary substantially across clinical sites, including readmission after hospitalization for
heart failure [Ross et al., 2008], mortality following surgery for colorectal cancer [Schootman et
al., 2014], graft failure after liver transplantation [Asrani et al., 2013], and medication adherence
rates among diabetes patients [Sherman et al., 2011]. As a result, generally applicable methods to
improve the transportability of clinical prediction models could have a large practical impact on a
wide range of areas in clinical medicine.

Improving prediction model transportability with sequential model updating. Generalized linear
mixed-effects models, also known as longitudinal or hierarchical models, are well-established in
the literature for accounting for clustered observations, such as would occur when patients at
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specific clinical sites are more similar to each other than to the overall population, in the context
of explanatory models [Fitzmaurice, Laird, & Ware, 2011]. However, their utility for improving
the transportability of prediction models is less clear, because predictions on novel clusters are
based on the hypothetical mean cluster. As a result, there is no heterogeneity across clusters for
out-of-sample predictions, even though the model is technically capable of allowing for such
heterogeneity. Thus, any improvement in prediction accuracy that results from using mixedeffects models is generally because of shrinkage effects, rather than incorporating knowledge
about cluster-specific differences.

One potential approach to the problem of prediction in novel clusters is sequential model
updating. Under sequential updating, predictions are made on individuals using the best available
model at that time. Then, when their outcome data become available, they are systematically
incorporated back into the model. As a result, novel clusters become incorporated into the data
sample over time, allowing for predictions that account for cluster-specific differences. In
practice, sequential model updating would likely involve incorporating the prediction model into
an electronic health records system (EHR) that is integrated across multiple clinical sites, so that
outcome data could be automatically captured and incorporated into the model. However, the
expected improvement in prediction accuracy that would be achieved through sequential model
updating remains unknown. Thus, given the large upfront financial costs and logistical challenges
of implementing such a system, it is important to quantify these potential gains, as well as the
conditions under which these gains can be maximized.

Simulation study. We sought to quantify the potential improvement in prediction accuracy that
might be expected with sequential model updating using a simulation study. Briefly, we
simulated a population of patients who are clustered in different clinics. These patients were
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randomly split into derivation and validation cohorts. Standard, non-updating prediction models
were built in the derivation cohort and then tested in the validation cohort. The same models were
then allowed to update periodically to see whether prediction accuracy improved. This process
was then repeated 1,000 times to assess the variability of the results. Finally, the sensitivity of the
results to changes in the value of parameters for the data-generating process was assessed.

METHODS
Overview. In our simulation, we aimed to develop a model to predict the outcome Yij, which
represents a generic, continuous clinical outcome for patient j at clinic i. Yij is dependent on X1ij, a
known patient-level predictor; X2ij, an unknown patient-level predictor; and Ni, the size of the
clinic. Note that X1ij and X2ij can also be interpreted as linear combinations of important
predictors, rather than just a single predictor. Clustering of the outcome is induced by a cliniclevel random intercept b0i and random slopes b1i and b2i. From 500 total clinics in the population,
20 were randomly selected to make up the “derivation” cohort. Using the derivation cohort, we fit
both updating and non-updating versions of models with fixed effects only, as well as those with
random intercepts and random slopes. These models were then tested on the remaining clinics,
which comprised the “validation” cohort. For each combination of parameter values, the
simulation was run 1,000 times to estimate the degree of variability in the results. All simulations
were performed using R 3.1.1 [R Development Core Team, 2014].

Mixed-effects modeling. Generalized linear mixed-effects models account for clustering in the
outcome by treating some model parameters as random, rather than fixed across the population.
These models typically follow the form:
(

)

,
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(1)

where (

) is a function of the outcome for individual j at clinic i,

is a vector of random effects,

is a vector of residual errors, and

is a vector of fixed effects,
and

are observed design

matrices relating to the fixed and random effects, respectively [Fitzmaurice et al., 2011]. Random
effects are typically modeled parametrically as

(

), where

is the variance-covariance

matrix. Use of this parametric structure for the random effects is typically more efficient than
cluster-level fixed effects, making it especially useful in settings where there are a large number
of clinical sites.

Sequential model updating. The primary advantage of combining a sequential model updating
approach with generalized mixed-effects models is that it allows the model to automatically
calibrate to local conditions, thus improving the transportability of the model, without the need to
recruit additional cohorts for constructing and validating a prediction model at each individual
site. Additionally, predictions at individual sites are able to “borrow strength” from data at other
sites to avoid the overfitting that might occur if separate models were fit at each site. One method
of achieving model updating that has been studied in the literature is dynamic logistic regression,
in which posterior values for Bayesian model parameters at time t are used to construct priors at
time t + 1, when new data have become available [McCormick, Raftery, Madigan, & Burd,
2012]. However, there are a number of approaches to estimation that could be used to achieve
model updating; in this simulation, we are focusing on the simple method of re-fitting the original
model at time t + 1, after incorporating additional data from the predictions that have been made
since time t. This choice in estimation allows for a more direct comparison of updating and nonupdating models, because all other features of the models are identical.

Data-generating process. For all simulations, we first generated a population of 500 clinics, each
with Ni patients, where:
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⌈

(

)⌉.

(2)

The log-normal distribution ensures that there are a large number of smaller clinics, with a small
number of very large clinics. The value for
size, was fixed at ln(65), while the value for

, where exp(

) is equivalent to the median clinic

was fixed at ln(2), in order to ensure a range of

clinic sizes of approximately 10 to 500 patients. These values were thought to be reflective of a
typical clinical scenario.

Next, clinic-level random intercepts and slopes were generated from a multivariate normal
distribution, as follows:
{

}

(

),

(3)

where b0i is the random intercept, b1i is the random slope for X1ij, and b2i is the random slope for
X2ij, and the variance-covariance matrix is:

[

].

(4)

The correlation between the random intercept and random slopes,

, was fixed at a moderate

value of 0.3, which was felt to be similar to what might be observed in practice. However,
sensitivity analyses demonstrated that the results were insensitive to increases or decreases in the
value of the correlation (data not shown). Additionally, we determined that having the correlation
between the random slopes differ from the correlation between the random intercept and random
slopes would not have a substantial impact on the results (data not shown), so the same value for
all correlations was used for model simplicity. After clinic-level random effects were generated,
patient-level variables were generated. First, X1ij and X2ij were generated as

(

) variables. The

variance was fixed at 1 for all parameter combinations in order to provide a reference point for
easier interpretation of the values of other parameters. We varied
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and

in order to determine

Figure 4.1. Summary of data-generating process. Variables enclosed in squares are fully observed,
variables enclosed in circles are unobserved, and variables enclosed in rounded rectangles are partially
observed.

the impact of different relative strengths of clinic-level heterogeneities, compared to patient-level
factors.

Then, the outcome Yij was generated as:
(
where

)

(

)
(

are independent errors distributed as

( )

,

) and the value of

(5)
was chosen such

that the error terms comprise 20% of the total variance in Yij. Clinic size is associated with the
outcome through the function f, with:
( )
where

is a scaling factor such that ( )

simulations, so that

and

( ( )
(

̅̅̅̅̅̅̅̅
( )),
). The value for

(6)
is fixed at 1 across all

gain the interpretation of the impact of X2ij and clinic size on the

outcome, respectively, relative to the impact of X1ij. Note that the overall intercept across all
clinics,

, was defined as equal to 0 and is thus not included in Equation 5. The data-generating

process is summarized in Figure 4.1.
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Parameter values. The main parameters that were varied for our simulation were

and

,

which controlled the relative impact of patient-level factors and clinic-level heterogeneities on the
outcome. Three values of each parameter were examined—0.5, 1, and 2 for
0.5 for

, and 0, 0.25, and

—for a total of 9 main parameter combinations. The values of these parameters can be

interpreted relative to the size of the variance in X1ij, which was fixed at 1. Additionally,

and

were fixed at zero for these main parameter combinations, so that the effects of unknown patientlevel factors and clinic size on the results could be examined in isolation. When
zero,

was equal to

was also set equal to zero, so that there was no effect of X2ij on Yij; when

equal to zero,

was set to be equal to

. We considered

,

,

was not
, and

to be the “base” parameter combination, and sensitivity analyses for individual parameters were
based on this combination of parameter values.

Later, we separately assessed the impact of non-zero values for
examined values of √

and

. Specifically, we

, 1, and √ for both parameters. These values were selected for greater

interpretability, as the relative contribution of X2 and
proportional to

and

( ) to the total variance in Yij was

, respectively. Thus, for example, when

√ , X2ij is contributing

twice as much to the variance in Yij as is X1ij. This set of parameter values likely covers the full
range of what could reasonably be expected in practice, given that the prediction models were
being rigorously constructed in the first place. For this set of parameter combinations,

and

were fixed at their base values.

Finally, we assessed the impact of varying update intervals in an attempt to reflect longer time
lags between predictions and the occurrence of the outcome that might take place in certain
clinical scenarios, such as those with survival-type outcomes. We examined values of 250, 500,
1,000, and 5,000 for , the number of predictions made between rounds of updating for updating
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models, as described below. We used

= 500 as the base value for all previously described

parameter combinations.

Prediction models. We randomly selected 20 clinics—stratified by clinic-size quintile,

—for

the derivation cohort, mimicking a multi-site cohort that might be used to develop a clinical
prediction model in practice. We selected 6 clinics from each of the bottom 2 quintiles, 3 clinics
from each of the next 2 quintiles, and 2 clinics from the upper quintile. We then built 3 prediction
models in the derivation cohort:
1) a linear model,

;

2) a Bayesian linear mixed-effects (BLME) model,
3) a second BLME model,

(

)

; and

.

BLME models were fit using restricted maximum likelihood, with non-informative flat priors for
the fixed effects and a non-informative prior for the random effects covariance matrix based on
the Wishart distribution. Estimation of BLME models was accomplished using the “blme”
package in R [Dorie, 2014]. Additionally, for simulations when
versions of the above models that included

, we also constructed

as a categorical fixed effect, since it was felt that

would be more likely to be observable than ( ) in practice.

All three models were tested in the validation cohort with and without sequential model updating.
Sequential model updating was achieved by making predictions on

patients, incorporating

outcome data on those individuals back into the derivation dataset, re-estimating the models, and
then making predictions on the next

patients. This algorithm was repeated until predictions had

been made on all patients in the validation cohort. For BLME models, this process was equivalent
to adding new data, and did not affect the model priors. The order of predictions was random
across the entire validation cohort, and each individual had an 80% chance to have his or her
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outcome data incorporated into the updating algorithm. We chose 80% because it realistically
allows for missing outcome data; this is reflective of missing outcome data that might occur when
utilizing a sequential model updating scheme in practice, where patients might be lost to followup before their outcomes are observed.

Assessment of model calibration. Accuracy of prediction models was based on assessments of
model calibration, with mean absolute error (MAE) being the primary metric [Wilmott &
Matsuura, 2005]. MAE was calculated as:
∑| ̂

|,

(6)

where n is the total number of individuals in the validation cohort. To improve the interpretability
of the results, we constructed a new metric, the “relative improvement” (RI) in MAE, for each
model as:
,
where
set, and

(7)

refers to the mean absolute error for the intercept-only model, as fit in the derivation
refers to the mean absolute error for the “true” model, which was considered to be the

model in Equation 4, minus the error term. Thus, the RI will typically range from 0 to 1 and can
be interpreted as the improvement of the current model over the intercept-only model, relative to
the improvement that would have been seen with the “true” model. Negative values for RI
indicate that the given model is worse than predicting the average value in everybody.

RESULTS
Population characteristics. There were 41,576 (SD 1,465) patients in the total simulated
population, on average, with 1,276 (SD 118) patients in the derivation cohort. Clinics ranged in
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Table 4.1. Clinic size distribution in the simulated population.
Clinic-size quintilea,b

0–20%

20–40%

40–60%

60–80%

80–100%

Minimum number
of patients in quintile

9 (2)

37 (2)

55 (2)

78 (3)

117 (5)

Percent of population
6.1 (0.3)
10.9 (0.5)
15.8 (0.6)
23.0 (0.6)
44.2 (1.2)
in quintile
a
Results are presented as mean (SD) across 1,000 simulations.
b
Clinic size distribution is not affected by varying the value of the main parameters.

size from 9 to 549 patients, on average. The median clinic had 66 patients, and 67% of patients
were in clinics in the top two quintiles of clinic size. Other characteristics of the distribution of
clinic size, which are reflective of the log-normal distribution selected, are shown in Table 4.1.
The effect of varying
increasing

and

on clinic-level clustering is shown in Figure 4.2; as expected,

, which represents the variance of the random intercepts, tended to yield greater

vertical displacement among the slopes, while increasing

, which represents the variance of the

random slopes, led to a more defined fanning pattern.

Main parameter results. As can be seen in Table 4.2, the prediction models explained a
substantial amount of the variance in the derivation cohort, ranging from an r2 of 0.25 to 0.80,
depending on the model and parameter combination. Furthermore, the addition of random effects
consistently led to dramatic improvements in the model r2 in the derivation cohort, creating the
initial appearance of improved model performance. However, because all out-of-sample
predictions are made assuming that new clinics have the mean value for their random intercept
and slope, the addition of random effects led to virtually no improvement in the accuracy of
predictions in the validation cohort, with mean RI at 33% to 34% for all non-updating models for
the base parameter combination. In contrast, use of sequential model updating led to dramatic
improvements in RI for both BLME models, across all parameter combinations tested (Figure
4.3).
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Figure 4.2. Effect of
and
on clinic-level clustering. Each point represents an individual patient at
one of the 20 clinics in the derivation cohort for a single simulation run. Lines represent the actual
relationship between X1ij and Yij at each derivation clinic. The center figure represents the base
parameter combination.

Table 4.2. Mean r2 for non-updating models in derivation cohort across all main parameter combinations.
a

Model

a

0.42 (0.11)
0.34 (0.10)
0.5
0.61 (0.08)
0.64 (0.07)
(
)
0.80 (0.04)
0.80 (0.04)
0.47 (0.09)
0.38 (0.08)
0.25
0.69 (0.06)
0.71 (0.05)
(
)
0.80 (0.04)
0.80 (0.04)
0.55 (0.06)
0.42 (0.06)
0
0.80 (0.02)
0.79 (0.03)
(
)
0.80 (0.02)
0.80 (0.03)
a
Results presented as mean (SD) over 1,000 simulations.
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a

0.25 (0.09)
0.68 (0.07)
0.79 (0.04)
0.27 (0.08)
0.73 (0.06)
0.79 (0.04)
0.29 (0.06)
0.79 (0.04)
0.79 (0.04)

Figure 4.3. Relative improvement in MAE for both updating and non-updating models across all main
parameter combinations. Plots show the density of values for relative improvement in MAE across 1,000
simulations, with horizontal bars representing the mean value.

As can be seen in Figure 4.4, gains in prediction accuracy from sequential model updating were
seen across all clinic-size quintiles, although the greatest improvement was seen in the largest
clinics. This pattern likely reflects the fact that improvements from updating were seen relatively
rapidly, with approximately 90% of the total gains in predictive performance for both BLME
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Figure 4.4. Relative improvement in MAE by clinic-size quintile. Plots show the density of values for
relative improvement in MAE across 1,000 simulations, with horizontal bars representing the mean value.
These results are for the base parameter combination.

models occurring after about 10 predictions at a given clinic (Figure 4.5). Because there were 480
clinics in the validation cohort and the model was updated after every 500 predictions, model
updates occurred after almost every prediction, on average, especially at smaller clinics.

Effect of model misspecification. When there was an unknown patient-level factor impacting the
outcome (i.e.

), sequential model updating was less effective (Figure 4.6). However,

updating models still were more accurate than non-updating models for all values of
the outcome be dependent on clinic size (i.e.

. Having

) led to worse performance of non-updating

BLME models, with these models performing worse than intercept-only models with large values
of

(Figure 4.7). However, updating BLME models showed no drop-off in prediction accuracy

with non-zero values of . Inclusion of clinic size quintile,

, as a categorical fixed effect led to

marked improvement in non-updating BLME models and even slight improvement in updating
BLME models, on average (Figure 4.8).
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Figure 4.5. Rate of improvement in prediction accuracy at a given clinic. This plot shows the mean
relative improvement in MAE for prediction j at clinic i, across 1,000 simulations. These results are for the
base parameter combination.
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Figure 4.6. Effect of
on model prediction accuracy. Plots show the density of values for relative
improvement in MAE across 1,000 simulations, with horizontal bars representing the mean value. The
parameters for
and
are fixed at their base values. Note that the relative contribution of X2ij to the
total variance in Yij, compared to X1ij, is equal to .
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Figure 4.7. Effect of
on model prediction accuracy. Plots show the density of values for relative
improvement in MAE across 1,000 simulations, with horizontal bars representing the mean value. The
parameters for
and
are fixed at their base values. Note that the relative contribution of ( ) to the
total variance in Yij, compared to X1ij, is equal to .
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Figure 4.8. Effect of on prediction accuracy for models that include . Plots show the density of values
for relative improvement in MAE across 1,000 simulations, with horizontal bars representing the mean
value. All models include
, which represents clinic-size quintile, as a categorical fixed effect. The
parameters for
and
are fixed at their base values. Note that the relative contribution of ( ) to the
total variance in Y, compared to X1, is equal to .
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Effect of varying the update interval. Results were fairly insensitive to changes in , the update
interval. Even when

= 5,000, or about 12.5% of the validation cohort, prediction accuracy in

updating BLME models was not substantially decreased (Figure 4.9). Furthermore, prediction
accuracy was consistent across all quintiles of clinic size with varying values of

(data not

shown). Finally, the rate of improvement in prediction accuracy only showed a notable decrease
when

= 5,000, when about 90% of total gains in prediction accuracy for both BLME models

occurred after about 20 predictions at a given clinic (Figure 4.10). Note that this value for
corresponds to a highly unlikely scenario where the model can only be updated about 8 times
over the course of using the model on a population of about 40,000 individuals.

DISCUSSION
Overview. In this simulation study, we sought to quantify the potential effect of sequential model
updating on the accuracy of clinical prediction models. Sequential updating of BLME models led
to uniform improvement in prediction accuracy across all parameter combinations examined.
Thus, it seems quite likely that substantial gains in the transportability of clinical prediction
models could be achieved through sequential updating of models that account for clinic-specific
heterogeneities, including differences in the mean level of the outcome as well as differences in
the association between known predictors and the outcome. However, the extent of the gains in
prediction accuracy from updating varied depending on the degree of misspecification of fixed
effects, indicating that use of sequential model updating will likely be more useful in clinical
scenarios where such misspecification can be minimized.

Impact of sequential model updating. Sequential model updating did not substantially improve
prediction accuracy with the linear model, performing similarly to all non-updating models.
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Figure 4.9. Effect of the update interval, , on model prediction accuracy. Plots show the density of values
for relative improvement in MAE across 1,000 simulations, with horizontal bars representing the mean
value. All other parameters are fixed at their base values.
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Figure 4.10. Effect of the update interval, , on the rate of improvement in prediction accuracy at a given
clinic. This plot shows the mean relative improvement in MAE for prediction j at clinic i, across 1,000
simulations, for different values of . All other parameters are fixed at their base values.
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As a result, flexible models with random effects were needed to account for the heterogeneities
across clinics. The accuracy of non-updating models decreased with increasing values of

and

; in short, greater heterogeneity across clinics led to worse performance for models that did not
take these differences into account. By contrast, updating BLME models showed greater
improvement in prediction accuracy when a larger proportion of the variation in the outcome was
explained by clinic-level heterogeneities. The BLME model with a random intercept showed
improved prediction accuracy with increasing values of
with higher values of

; however, its performance deteriorated

. This deterioration in accuracy with larger random slopes is not

surprising, because this model had no way to account for the random slopes that were present in
the data structure. Even so, the model was able to use its random intercept to account for a large
enough amount of inter-clinic variability to provide uniform improvement over non-updating
models and the linear updating model.

The BLME model with both a random intercept and random slope was nearly as accurate as the
“true” model across all main parameter combinations, with a mean RI ranging from 94 to 96%.
This was because the model was essentially equivalent to the data-generating model in these
cases, and updating occurred fast enough that predictions on most individuals in the validation
cohort were made with a fully calibrated model. Indeed, about 90% of the gains in prediction
accuracy were seen by about the 10th patient at a given clinic, so even small clinics were able to
see benefits from sequential model updating, and the majority of predictions at large clinics were
made with an accurate estimate of clinic-specific random effects. This rapid improvement in
prediction accuracy was largely sustained even with higher values of

, so overall prediction

accuracy in the validation cohort was preserved even when models were updated less frequently.
It should also be noted that this high level of prediction accuracy was sustained even when there
was no random slope in the data-generating process (
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= 0). Thus, there was not really much

downside to having an unnecessary random slope in the updating model, while having only a
random intercept when the data-generating process included both a random intercept and a
random slope led to decreased prediction accuracy.

Additionally, the variance of RI values across simulations tended to be lower in updating models
than in non-updating models. The variance in prediction accuracy decreased with each additional
random effect in the model, as well. This speaks to another important feature of sequential model
updating, which is the ability to overcome sampling bias to produce models that perform more
consistently. In the non-updating models, the prediction accuracy was largely dependent on
whether the clinics that comprised the derivation cohort happened to be representative of the
overall population. In simulations where estimates of

and

were very different from their

true values due to random sampling, prediction accuracy for non-updating models in the
validation cohort tended to be worse (Figures 4.11–4.13). However, sequentially updating models
were able to overcome initial sampling bias by improving model calibration over time.

Impact of model misspecification. When an unknown patient-level factor was added to the data
structure (

), updating BLME models had a decrease in prediction accuracy; however, they

still performed better than non-updating models for all values of

. In short, it is still important

to be diligent when selecting covariates and their specifications for a sequentially updating model,
as models that are closest to the true data-generating process will still perform the best. However,
most realistic clinical scenarios involve unknown predictors and misspecification, so the fact that
sequential model updating still led to improvements in prediction accuracy under these conditions
suggests that it may be a useful strategy in the real world.
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Figure 4.11. Relationship between bias in estimated model coefficients and prediction accuracy for the
linear model. Each point represents one of 1,000 total simulations for the base parameter combination, and
best fit lines are shown in red. The left panel shows the bias in the estimated intercept from the derivation
cohort compared to the true value in the overall population, while the right panel shows this bias for the
estimated slope.

Figure 4.12. Relationship between bias in estimated model coefficients and prediction accuracy for the
BLME model with random intercept. Each point represents one of 1,000 total simulations for the base
parameter combination, and best fit lines are shown in red. The left panel shows the bias in the estimated
intercept from the derivation cohort compared to the true value in the overall population, the middle panel
shows this bias for the estimated slope, and the right panel shows this bias for the estimated variance of the
random intercepts.
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Figure 4.13 Relationship between bias in estimated model coefficients and prediction accuracy for the
BLME model with random intercept and slope. Each point represents one of 1,000 total simulations for the
base parameter combination, and best fit lines are shown in red. Starting from the top left panel and
moving in clockwise fashion, the panels show the bias in the estimated intercept, slope, variance in the
random slopes, and variance in the random intercepts, as compared to the true value in the overall
population.

Clinic size or volume may be related to outcomes in a number of clinical scenarios, such as
hospital mortality rates for acute myocardial infarction or surgical mortality rates [Birkmeyer et
al., 2002; Silber et al., 2010]. While other clinic-level effects can be accommodated by random
intercepts and slopes, we were concerned that clinic size might behave differently because it is
directly related to the probability of observing the data in the first place. Larger values of

led to

worse performance of non-updating BLME models, while updating BLME models showed no
deterioration in performance. In non-updating BLME models, the effect of sampling bias was
actually amplified because differences due to clinic size were incorporated into the model as
random effects, with greater bias in the estimated random effects covariance matrix leading to
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worse prediction accuracy (Figures 4.14 and 4.15). However, in updating models, these initial
biases were diminished over time because the model was continually being calibrated to the
overall population, such that the majority of predictions were unaffected by the initial biases. As a
result, inclusion of

was required to improve the accuracy of non-updating BLME models, but

not practically necessary in the case of updating BLME models. These results also speak to the
general robustness of sequentially updating models that account for clinic heterogeneities; while
correct specification is still better, misspecification is not nearly as costly as it is with nonupdating models.

Challenges to incorporating sequential model updating in practice. Implementation of sequential
model updating in practice will likely involve many logistical and analytical challenges. In order
to work well, prediction models will likely need to be integrated into EHR systems, so they will
be able to automatically extract covariate data to make an initial prediction, and then
automatically extract outcome data to use for model updating. Furthermore, in order to
accommodate heterogeneities across sites, the EHR will need to either be standardized across all
of the sites, or compatible enough to allow for communication of data. Additionally, the data
storage and security requirements for large amounts of data across multiple sites will likely be
quite complex. Certain analytic strategies—such as Bayesian dynamic regression, where posterior
distributions are estimated from dynamic priors in a fully online fashion [McCormick et al.,
2012]—could greatly reduce the data storage requirements, and, accordingly, the data security
concerns. However, more work is needed to determine the trade-offs in prediction accuracy that
might accompany this approach under certain scenarios. Finally, there will need to be a concerted
effort to communicate the effectiveness of this approach to the clinical community in order to
foster the necessary level of trust to overcome initial financial and logistical hurdles.
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Figure 4.14. Relationship between bias in estimated model coefficients and prediction accuracy for the
BLME model with random intercept, with clinic size influencing the outcome. Each point represents one of
1,000 total simulations with
√ , and best fit lines are shown in red. The left panel shows the bias in the
estimated intercept from the derivation cohort compared to the true value in the overall population, the
middle panel shows this bias for the estimated slope, and the right panel shows this bias for the estimated
variance of the random intercepts.

Figure 4.15 Relationship between bias in estimated model coefficients and prediction accuracy for the
BLME model with random intercept and slope, with clinic size influencing the outcome. Each point
represents one of 1,000 total simulations with
√ , and best fit lines are shown in red. Starting from the
top left panel and moving in clockwise fashion, the panels show the bias in the estimated intercept, slope,
variance in the random slopes, and variance in the random intercepts, as compared to the true value in the
overall population.
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The analytic challenges involved in sequential model updating are also likely to be quite
complex. Missing data, both for covariates and outcomes, will be an important issue to resolve, as
standard methods, such as multiple imputation [Groenwold, Donders, Roes, Harrell, & Moons,
2012; Moons, Donders, Stijnen, & Harrell, 2006], may be difficult to implement in the context of
a dynamic system. As a result, efforts to jointly model the updating process along with the
prediction model itself, analogous to methods for jointly modeling longitudinal and competing
risks data [Li, Elashoff, & Li, 2009], may be required. Alternatively, use of missing indicators
may be more useful than with standard models [van der Heijden, Donders, Stijnen, & Moons,
2006], because these parameters would be allowed to calibrate to the population over time.
However, further studies are needed to answer these questions empirically. Other important
analytic issues that would need to be resolved include how to incorporate new predictors or
specifications into a sequentially updating model; how much to weight historical data in a
population that is changing over time; how best to account for time lags between making
predictions and obtaining outcome data; and how to determine whether a model is not performing
well enough at a given site and needs to be replaced with a separate, newly derived model.

Study limitations. Although our simulation was based on a hypothetical predictor and outcome
variable, we tried wherever possible to mimic situations that might occur when developing and
utilizing a typical clinical prediction model. For instance, we utilized a log-normal distribution for
clinic size, so that there would be a larger number of small clinics than large clinics, and we
generated the derivation cohort to be similar in size and composition to what might be found in a
large multi-center cohort study. We also excluded some patients from contributing data to
updating models, to reflect the loss to follow-up that might occur in clinical practice. Finally, we
examined scenarios where the model was not correctly specified, which are likely to occur in
real-world applications.
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Despite these efforts, there are a number of limitations to our model. For instance, we did not
examine scenarios where heterogeneities across clinics were not normally distributed. It is
possible that standard BLME models might not perform as well in this scenario, leading to a
model that was less calibrated to local conditions, even after updating. However, research
studying the impact of misspecified parameterization of random effects on prediction accuracy
suggests that the standard multivariate normal assumptions should be reasonably robust
[McCulloch & Neuhaus, 2011]. Additionally, we assumed in our simulation that outcome data
that was not available for updating was missing completely at random, which may not hold in
practice. Future studies are needed to determine whether the prediction accuracy of sequentially
updating models will be worsened in scenarios where the probability of obtaining outcome data
for updating is dependent on model covariates or, especially, the outcome.

We attempted to cover a reasonable range of parameter values in our analysis; however, it is
possible that our results will not extrapolate to values outside of the tested ranges. Additionally,
to reduce computational burdens, we focused on a simplistic model: a single continuous predictor
and a continuous outcome. Clearly, clinical prediction models in the real world will have multiple
covariates, and many will have more complex outcomes. The precise gains in prediction accuracy
from sequential model updating will likely vary depending on the particular structure of the data
in question. Finally, sequential model updating in practice will have to deal with a lag between
when predictions are made and when outcomes are observed. It is possible that long lag periods
relative to the frequency of updating will decrease the rate at which prediction accuracy
improves. As a result, sequential model updating may be less useful for prediction models with
long lag times, especially at smaller clinics or in rapidly changing populations. We attempted to
assess the sensitivity of our results to long lag times by varying the update interval, , and large
improvements in prediction accuracy with updating BLME models were still seen even at the
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highest values of . Even with these positive results, though, the exact effect of time lags on the
performance of sequentially updating models will need to be formally addressed in future
research. Despite these limitations, we are confident that sequential model updating will prove to
be a useful approach for a broad set of clinical scenarios.

Future directions. Many of the limitations and challenges discussed above provide an excellent
framework for future research in this area. More simulations are needed to test the performance of
sequential model updating in the context of clustered populations that change dynamically over
time, which will be more reflective of actual patient populations. Additionally, more rigorous
study of time lags in outcome variables and approaches to handling missing data are needed.
Furthermore, more explicit comparison of different specific modeling approaches, such as formal
Bayesian dynamic approaches [McCormick et al., 2012], model averaging techniques [Raftery,
Gneiting, Balabdaoui, & Polakowski, 2005], non-parametric strategies [Ryu, Li, & Mallick,
2011], and machine learning methods [Hastie et al., 2009] are needed. Finally, these approaches
will need to be tested in a variety of empirical studies to determine the extent to which theoretical
gains are likely to be realized in practice.

Conclusions. In conclusion, sequential updating of models that accommodated clinic-level
differences led to improved prediction accuracy in the overall population. The extent of the
improvement in prediction accuracy that was observed with updating mixed-effects models
depended on the relative impact of clinic-level and patient-level factors on the outcome as well as
the degree of model misspecification; however, updating mixed-effects models were uniformly
superior to non-updating models as well as updating models with only patient-level fixed effects.
Gains in prediction accuracy tended to occur rapidly, leading to improvements at small clinics as
well as large clinics. While there are many logistical and analytical questions to resolve, the
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potential for a sequential model updating approach to improve the transportability of clinical
prediction models seems quite promising.
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CHAPTER 5. CONCLUSIONS

In Chapter 2, we found that baseline behavioral factors, health care utilization, and health quality
were associated with longer time to maintenance dose in patients initiating warfarin therapy,
while in Chapter 3, we discovered the difficulty of developing a model to predict prolonged dose
titration in these patients. Our results in Chapter 4 suggested that sequential model updating of
mixed-effects models can lead to substantial improvement in prediction model transportability. In
addition to these specific results, however, a major focus of this dissertation was using warfarin
response as an example of therapeutic effectiveness research in general. Thus, while the studies in
Chapters 2 and 3 are designed to address specific questions about patients initiating warfarin
therapy, the lessons gleaned from these studies can apply to the field of therapeutic effectiveness
research more broadly. Similarly, the methods examined in Chapter 4 would be expected to
extend beyond models of therapeutic effectiveness to clinical prediction models more generally.

In Chapter 2, we examined the genetic, clinical, and social factors associated with time to
maintenance dose (TTM) for patients starting warfarin therapy. The results highlight the
importance of considering non-genetic factors when studying outcomes related to anticoagulation
control. While most of the previous research on TTM had focused on genetic variants that have
been previously found to affect the required therapeutic dose of warfarin [Cavallari et al., 2011;
Higashi et al., 2002; Jorgensen et al., 2009; Limdi et al., 2008; Meckley et al., 2008], none of the
genetic variants we examined were significantly associated with TTM. Instead, TTM appeared to
be more related to baseline behavioral factors, health care utilization, and health quality. Of
particular importance was the finding that having previously been on warfarin was associated
with longer, rather than shorter, TTM. This new finding suggests that clinicians should be just as
vigilant in monitoring these patients, even though they have more experience with warfarin
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therapy. These findings are salient for the broader field of therapeutic effectiveness research, as
well. In an era of “personalized medicine” [Crews, Hicks, Pui, Relling, & Evans, 2012], it is
important that research on the impact of genetic factors on the effectiveness of a given therapy
not come at the expense of research on non-genetic factors, which may be just as important, if not
more so, in clinical practice.

When conducting this study, we had hoped to identify potential targets for future interventions for
improving TTM in patients on warfarin therapy by examining the effect of post-initiation factors,
such as changes in interacting medications or changes in diet. Our results were disappointing
here, because none of the post-initiation factors examined were significantly associated with
TTM. These results further suggested that changes likely did not occur frequently enough in the
early stages of warfarin therapy to affect TTM or that clinicians responded to these changes with
appropriate dose changes. However, it is still possible that these factors might be more important
for determining anticoagulation control in patients in the maintenance phase of therapy, when
monitoring is less frequent and dose titration is not active. Future research on this topic will need
to ensure correct specification of time-varying factors to avoid immortal time bias as well as
adjustment for variable INR monitoring frequency to avoid interval censoring bias.

In Chapter 3, we developed and externally validated a model to predict prolonged dose titration in
patients initiating warfarin therapy. While the model developed appeared to perform well in the
derivation cohort, even when assessed using cross-validation, it did not perform as well in the
external validation cohort. As a result, it is unlikely that the model will be useful in clinical
practice. Post-hoc analyses suggested that model performance varied substantially across clinical
sites, with marked differences in the AUC among the anticoagulation clinics in the validation
cohort. These sites differed from each other in terms of outcome prevalence and patient
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characteristics, and the most important predictors of prolonged dose titration in the validation
cohort were somewhat different from the derivation cohort. Although the prediction model itself
will not be useful for clinical practice, our results offer an important cautionary tale on the
essential need for external validation when developing prediction models.

Furthermore, the rigorous decision-theoretic approach that we used to examine the clinical utility
of our model will still be useful, both to clinicians and to future researchers. An understanding of
the risk threshold can help clinicians formally think about the relative costs of financial and
monitoring burdens for their patients and then come to a decision about optimal treatment choice
based on the overall prevalence of the outcome. Additionally, future prediction models on
therapeutic effectiveness will likely be more easily incorporated into clinical practice if they can
demonstrate their usefulness to the clinical decision-making process with metrics such as relative
utility. More research is certainly needed to develop summary metrics of prediction model
performance that are rooted in decision theory; it is likely that clinicians will be more trusting of
these methods when they become simpler and more intuitive.

The substantial variability in the performance of our prediction model across clinical sites in
Chapter 3 provided an unexpectedly good motivation for the methodological work done for the
project described in Chapter 4. Poor transportability is a pervasive problem for clinical prediction
models, and, generally, most research has focused on developing new models or finding new
predictors that can provide incremental improvement, without addressing the fundamental
challenge of accounting for variability in the relationship between predictor variables and
outcomes in different locations, across clinical domains, and over time. With recent technological
advancement in and widespread adoption of electronic health record (EHR) systems [Kukafka et
al., 2007], it has become easier to imagine systems that utilize EHR data to improve predictions
95

made across integrated health systems. Essentially, prediction models could be incorporated into
an EHR system, used to make predictions on patients within that system, and then updated
sequentially as outcome data on those patients become available. Flexible models, such as mixedeffects models, would thus be able to use this updated information to calibrate to local conditions,
such as individual clinics or even individual patients in some settings, over time, while using the
data from the overall population to avoid overfitting at any one site.

Because integrating a clinical prediction model into an EHR would likely involve substantial
upfront costs, we felt it was important to quantify the potential gains in prediction accuracy that
could be achieved by sequential model updating. We achieved this aim through a simulation
study, presented in Chapter 4, comparing the prediction accuracy of several updating and nonupdating models for a generic clinical outcome. The results suggested that sequential updating of
models that account for heterogeneity across clinics in mean outcome levels and predictoroutcome associations can lead to dramatic improvements in prediction accuracy. Furthermore,
while the extent of the gains varied depending on the degree of model misspecification—
including misspecification of the random effects structure, the presence of unknown patient-level
predictors, and the presence of unknown or misspecified clinic-level predictors, such as clinic
size—there were no scenarios we examined in which updating models performed worse than nonupdating models. Thus, sequential model updating has the potential to be a broadly applicable
approach to improving clinical prediction modeling.

However, there remains important methodological work to be done before sequential model
updating approaches can be widely adopted in clinical practice. For instance, the length of time
between when predictions are made and when outcomes are experienced could impact the
feasibility of sequential model updating in certain clinical scenarios. Additionally, methods to
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deal with missing data and outcome-dependent data collection will need to be tested. Different
types of statistical models will also need to be compared based on how well they perform in an
updating framework. Metrics to decide how to incorporate new predictors into established models
and to determine whether stratified or unified models are needed across diverse patient
populations will need to be developed. Finally, empirical demonstration projects are also likely to
reveal unanticipated logistical and analytic challenges that can form the basis for future
methodological research. All of this work will help to clarify the types of clinical situations where
sequential model updating would be expected to be most useful and how best to implement this
approach in practice.

Ultimately, adaptation is likely to be a common theme for therapeutic effectiveness research
moving forward. Anticoagulation research is shifting in focus from how to determine a patient’s
warfarin dose to how best to use warfarin as one of a number of therapeutic alternatives.
Although it proved to be less useful for predicting prolonged dose titration in patients starting
warfarin therapy, genetic and genomic data will likely be more successful at predicting who is
likely to respond to therapy or experience side effects for other specific conditions. In contrast,
methods to improve medication access and adherence will likely be more important for
conditions where genetic factors are less useful. To maximize their clinical utility, prediction
models will need to be able to adapt to heterogeneities in patient populations and practice patterns
in different locations as well as changes in clinical practice over time. It is our hope that the work
in this dissertation and the work that will arise from it represent a small step toward making
therapeutic effectiveness research more effective.
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APPENDIX

List of medications considered to interact with warfarin. Potentially interacting drugs were
identified from the Physicians Desk Reference, Drug Facts and Comparisons 4.0, and MEDLINE
literature searches as of the time that patients were enrolled in the study.

Drug Name
(CHOLESTROL LOWERING MED.)
LIPITOR
ASTORVASTATIN
ATORVAST
ATORVASTATIN
ATORVASTATIN CA/LIPITOR
ATORVASTATIN CALCIUM
ATORVASTIN CALCIUM
ATOVASTITIN CALCIUM
CRESTOR
CRESTOR/ROSAVASTATIN
HIGH CHOL. MED./ LIPITOR
LESCOL
LESCOL 20MG QD
LESCOL/FLUVASTATIN
LIPITOL
LIPITOR
LIPITOR 20MG GD
LIPITOR 40MG QD
LIPITOR/ATORVASTATIN CA
LIPITOR/ATORVASTATIN CALCIUM
LIPOTON
LOSCOL
LOVASTANTIN
LOVASTATIN
MEVACOR
PRAVACAL
PRAVACHOL
PRAVACHOL 80 MG DAILY
PRAVACHOL/PRAVASTATIN
PRAVACHOT
PRAVASTATIN/PRAVACOL
PRAVOCHOL

Drug Name (cont.)
IMURAN
INDOCIN (X 7 DAYS)
ISONAL
KETOCONAZOLE
KETOCONAZOLE (PILLS)
KETOCONAZOLE CREAM
KOFECOXIB
LAMISIL
LASIX
LASIX INCREASED
LEVAGUIN
LEVAQUIN
LEVAQUIN 750
LEVAQUIN/ANTIBIOTIC
LEVOFLOXACIN
LEVOFLOXCIN
LEVOQUIN
LEVOQUIN (TILL 10-16)
LEVOTHROYOXINE
LEVOTHYROPINE
LEVOTHYROXIN
LEVOTHYROXINE
LEXA PRO/SELECTIVE SERETONIN
REUPTAKE
LISINIPRIL/HCTZ/ZESTORETIC
LISINOPRIL/HYDROCHLROTHIAZIDE/ZEST
ORETIC
MASOCORT AC / NASAL STEROID
MAXIDE
MEDROL
METHIMAZOLE
METHIMAZOLE THYROID
METHONIDAZOLE
METHYLPHENIDATE
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PREVASTATIN
PROVOCHOL/PRAVASTATIN
ROSUVASTATIN/CRESTOR
SIMAVASTATIN
SIMVASTATIN
SIMVASTATIN (ZOCOR)
SIMVASTIN
ZOCOR
ZOCOR 20 MG PO QD
ZOCOR/SIMVASTATIN
ZOCOR/SIMVASTIN
ZOLCOR
(CANCER TREATMENT)
"CARBOPLATIN
(CHEMOTHERAPY) S-FU
(HYDROCODONE-APAP)
(PAIN MED.) HYDROCO/APAP
(TERBINAFINE)
A.S.A.
A.S.A. 81
ACARBASE
ACCOLATE
ACCURETIC
ACETAMINOPHEN
ACETAMINOPHIN
ADVIL
ADVIL COLD PILLS
ALDACTAZIDE/SPIRONOLACTONE
ALDACTONE
ALEVE
ALFALFA
ALKA SELTZER PLUS COLD MED.
ALLAPURINOL
ALLIPURINOL
ALLOPURINOL
ALLUNOPURINOL
ALLUPROPINOL
AMIADARONE
AMIODARON
AMIODARONE
AMIODARONE HCL
AMIODARONE HCL.
AMIODIONE
AMIODORONE
ANTIBIOTIC/METRONIDAZOLE
ANTIBIOTICS-

METHYL-PREDINZONE
METOLAZONE
METRINIAZOLE
METRONIDAZOLE
METRONIDAZOLE X 8 WKS.
MOTRIN
MULTI-SYMPTOM NON-ASPIRIN COLD
MEDICINE
NAFCILLIN
NAPROSIN
NAPROSYN
NAPROXEN
NAPROXIN
NAPROXYN
NASACORT
NASOCORE
NASOCORT
NELFINAVIR
NELFINAVIRMESYLATE/NIRACEPT
NEOMYCIN
NIZOVAL CREAM
NORVIR
OLMESARTAN
MEDOXOMIL/HCTZ/BENICAR
OMACOR (FISH OIL) RX
OMAPRAZOLE
OMEGA 3 FATTY ACIDS
OMENPRAZOLE
OMEPRAZOLE
OMEPRAZOLE (GERD)
OMEPRAZOLE/PRILOSEC
OMEPROZOLE
OMESARTAN/HYDROCHLOROTHIAZIDE
ORTHOTRYCYCLINE
OXALIPPATIN
OXYCODONE W/APAP
OXYCODONE/APAP
PANADOL FOR COLD
PARACETAMOL
PAROXETINE
PAXIL
PCE
PENICILLIN (PENECILLIN)
PERCOCET
PERCOCET (OXYCODONE-APAP
PERCOCET PRN
PERCOCET-POSTOP PAIN
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SULFAMETHOXOZOLE/TRIMETHOPRI
M
ANTIDEPRESSANT-CELEXA
APA
APA/TYLENOL
ARTHROTEK
ASA
ASA (FOR PROCEDURE)
ASA 81 MG PO QD
ASA 81MG.
ASA, 81MG
ASIPRIN
ASPIRIN
ASPIRIN (LOW DOSE)
ASPRIN
AZATHIOPRINE
AZATHIOPRINE/IMURAN
AZITHROMYCIN
AZITHROMYCIN-ONE DOSE ONLY
AZMACORT
BABY ASA
BACTRIM
BACTRIM
SS/SULFAMETHOXAZOLE/TRIMETHO
PRIM
BACTRIM/SULFAMETHOXAZOLE/TRI
METHOPRIM
BACTRUM
BENICAR
BEXTRA
BEXTRA 10MG QD
BEXTRA/VALDECOXIB
BEXTRA/VALDECOXILO
BIAXIN/CLARITHROMYCIN
BICALURIMINE
BICALUTAMIDE
CAPECITABINE
CARAFATE
CARBOPLATIN
CASODEX
CASODEX/BICALUTAMIDE
CEFAZOLIN
CEFRIAXONE
CEFTRIAXONE
CELEBREX
CELEBREX 200MG
CELEBREX/ CELECOXIB
CELECOXIB/CELEBREX

PERCOCETS
PERIOSTAT
PESTO-CET (PERCOCET)
PHENOBARBITAL
PHENYTOIN
PHENYTOIN SODIUM
PHYTONADIONE
PIROXICAM
PIROXICAM/FELDENE
PIROXICAM/FELDINE
PIROXICAN
PIROXICN
PLACIDEL
PREDNISOLONE EYEDROPS
PREDNISONE
PREDNIZONE
PREDUIBONE
PREDUISONE
PRILOSEC
PRILOSEC 11/29-12/12/04
PRIMIDONE

PRIOXICAM
PROPAFANONE
PROPAFENONE
PROPAFENONE (RYTHMOL)
PROPAFENONE-RYTHMOL
PROPAFERONE
PROPANOLOL
PROPANOLOL ER
PROPOXYPHENE.
PROPRANOLOL
PROTOZONE
PROXICAM/FELDENE
PROZAC
QUININE
QUININE SULFATE
RANITIDINE
RANITIDINE HCL
RANITIDUIE
RANTITIDEINE
REFOCOXIB
REQUIP
REQUIP (RLS)/ROPINIROLE HCL
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CELEXA
CHEMOTHERAPY-TAXOL
CHLORPHENIRAMINE MALEATE
CHOLESTYR
CIPRO
CIPRO 3/29 -> 4/2/05
CIPROFLOXACIN
CITALOPRAM
CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN
CLELBREX
CLOBETASAL CREAM
COATED ASPIRIN
CONCERTA (PRN)
CORTISONE SHOT
CORTIZONE SHOT
CYCLOSPORIN
DARVOCET
DARVOCET-N
DECADRON
DEPAKOTE (BIPOLAR)
DETROL
DETROL-LA
DEXAMETHASONE
DEXAMETHASONE/DECADRON
DEXAMETHAZONE
DILANTIN
DILANTIN/PHENYTOIN
DIURETIC LASIX
DOXERCALCIFEROL (FOR
PARATHYROID)
DOXYCYCLINE
DOXYCYLINE
ECOTRIN
EFUDEX
ENDOCET
ENDOCET/PERCOCET
ENDOCOT (STOOL SOFTENER)
ENSURE
ERYTHROMYCIN
ERYTHROPOIETIN
ERYTHROPOIETIN/EPOGEN
ERYTHROPOIETIN-EPOGEN
ESTRACE
ETODOLAC/FOR PAIN
ETOPOSIDE
EXCEDRIN TENSION HEADACHE

REQUIP/REPINIROLE
REYATAZ
REYATAZ (ATAZANAVIT)
RHYTHMOL
RHYTHMOL 300MG TID
RIBAURIN
RIBAVIRIN
RIFAMPIN
RITALIN
RITONAVIR (NORVIR)
RYTHMOL
SANDOSTATIN
SERTRALINE
SPIRONALACTONE
SPIRONOLACTONE
SPIRONOLACTONE/HCTZ
SULFA
SULFAMETHOXAZOLE
SULINDAC
SUSTIVA
SYNTHROID
SYNTHROID/LEVOTHYROXINE
SYNTHROID-1 MG.
TAXOL
TEQUIN/GATIFLOXACIN
TERBINAFINE HCL
TERBINAFINE/LAMISIL
TEROZASIN
TESTOSTERONE (ANDRODERM PATCH)
TESVOSVERONE
TETRACYCLINE
THALIDOMIDE
THERAFLU
TOLTERODINE TARTRATE/DETROL
TOOK 1ST NAPROSYN-"
TOOK 2ND RELAFEN-"
TOPAMAX (MIGRANES)
TRAMADOL
TRAMADOL/CENTRAL ANALGESIC
TRAZAD
TRAZADONE
TRAZADONE HCL
TRAZODONE
TRENTAL 400MG PO TID
TRIAMCINOLONE
TRIAMCINOLONE CREAM
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EXTRA STRENGTH TYLENOL
FLAGYL
FLAGYL/METRONIDAZOLE
FLORAZEMIDE
FLUDROCORTISONE ACETATE
FLUOXETINE
FLUROSEMIDE
FLUROSIMIDE
FRESH FROZEN PLASMA
FUOROSEMIDE
FUROSEMIDE
FUROSEMIDE / DUIRETIC
FUROSEMIDE 40MG DAILY
FUROSEMIDE/DIURETIC
FUROSEMIDE/DUIRECTIC
FUROSEMIDE/DUIRETIC
FUROSEMIDE/H20 PILL
FUROSEMIDE/LASIX
FUROSEMIDE-DUIRETIC
FUROSIMIDE/H2O PILL
GATIFLOXACIN
GEMFIBROZIL
GENERIC PERCOCET
GLUCOSAMINE/CHONDROITIN
H2O PILL - LASIX (GENERIC)
H2O PILL-HYDROCHLOROTHIAZIDE
H2O PILLS/FUROSEMIDE
HALOPERIDOL
HCLT
HCT2
HCTZ
HCTZ (DIURETIC)
HCTZ (HYDROCHLOROTHIAZIDE)
HCTZ/HYDROCHLOROTHIAZIDE
HCTZ/TRIAMTERENE
HTCL
HTCZ
HYDR0CHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE (HCTZ)
HYDROCHLORTHESIDE/HCTZ
HYDROCHLORTHIA ZIOLE
HYDROCHLORTHIAZIDE
HYDROCHLORTHIZIDE
HYDROCHLOTHIAZID
HYDROCO/APAP

TRIAMCINOTONE CREAM
TRICOR
TRICOR/FENOFIBBRATE
TYLENOL
TYLENOL 3
TYLENOL 500
TYLENOL COLD
TYLENOL COLD & SINUS
TYLENOL PM
TYLENOL PM (PRN)
TYLENOL PRN.
TYLENOL SINUS
TYLENOL W/CODEINE
TYLENOL WITH CODEINE
TYLENOL/CODENE
TYLOX
ULTRACET
ULTRACET MCN 2 EVERY 4-6 HR. AS
NEEDED
ULTRAM
VALPROIC ACID
VICODAN
VIOX
VIOXX
VIRACEPT
VIT C
VIT E
VITAMIN C
VITAMIN E
VITAMIN K.
VYTORIN
XELODA
XELODA (XELODA)
ZANTAC
ZAROXALYN (METOLAZONE)
ZITHRO PAC
ZITHROMAX
ZITHROMYCIN
ZOLOFT
ZOLOFT/SERTRALINE
ZOSYN
ZOSYN ONE DOSE
Z-PAC
Z-PAC/ZITHROMAX
Z-PACK
Z-PACK ANTIBIOTIC (TOOK 9-23 TO 9-28)
Z-PACK-5 DA ONLY
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HYDROCORTISONE
HYZAAR
IBUPROFEN

Z-PAK/ZITHROMAX
ZYRTEC/CETIRIZINE
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